Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 1285. Отображено 100.
12-01-2012 дата публикации

Respiratory Syncytial Virus Antigenic Compositions and Methods

Номер: US20120009254A1
Принадлежит: Artificial Cell Technologies Inc

Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response.

Подробнее
26-04-2012 дата публикации

Continuous Cell Programming Devices

Номер: US20120100182A1
Принадлежит: Individual

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Подробнее
19-07-2012 дата публикации

Polyethylene glycol-based dendrons

Номер: US20120183578A1
Принадлежит: Rutgers State University of New Jersey

The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use.

Подробнее
01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells

Номер: US20120276155A1
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

Подробнее
01-11-2012 дата публикации

Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use

Номер: US20120276156A1
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens.

Подробнее
01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses

Номер: US20120276158A1
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.

Подробнее
01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers

Номер: US20120276159A1
Принадлежит: Selecta Biosciences Inc

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Подробнее
01-08-2013 дата публикации

Conjugates comprising an n-oxime bond and associated methods

Номер: US20130195791A1
Принадлежит: University of Kansas

Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R′ is derived from a compound comprising at least one reactive amide group, R″ is derived from a compound comprising at least one reactive aminooxy group, and X is H, C n H (n+2) or other atoms. Additional methods are also provided.

Подробнее
07-01-2021 дата публикации

Polymer adjuvant

Номер: US20210000934A1

The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.

Подробнее
12-01-2017 дата публикации

Bifunctional conjugate compositions and associated methods

Номер: US20170007684A1
Принадлежит: University of Kansas

Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.

Подробнее
10-01-2019 дата публикации

Methods and reagents to treat autoimmune diseases and allergy

Номер: US20190008900A1
Автор: Tian Xin Wang
Принадлежит: Individual

Compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy are described. The compositions and related methods comprise APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen. The compositions can be particle containing antigen and immunosuppressant. The compositions can also be linear polymer containing antigen and immunosuppressant.

Подробнее
27-01-2022 дата публикации

Methods, compositions and therapeutical vaccine for autoimmune diseases and allergy treatment

Номер: US20220025015A1
Автор: Tianxin Wang
Принадлежит: Individual

Compositions, reagents, formulations and methods to treat disease including autoimmune diseases and allergy are described. The compositions comprise an antigen causing immune intolerance, an immunosuppressant in a sustained release formulation. The methods, compositions, formulations and reagents to treat allergy also relate to applying the combination of allergen and immune activity enhancing agent in a sustained release formulation to a subject in need.

Подробнее
10-01-2019 дата публикации

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

Номер: US20190010190A1
Принадлежит:

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. 1. A method of treating a patient who has cancer , comprising administering to the patient an effective amount of an antibody specifically binding to an MHC class I or II molecule complexed with a HLA-restricted antigen consisting of the amino acid sequence of KIQEILTQV (SEO ID NO: 14) , wherein the cancer is selected from the group consisting of glioblastoma , renal cell carcinoma , melanoma , endometrial cancer , esophageal squamous cell carcinoma , pancreatic cancer , and urothelial cancer.2. The method of claim 1 , wherein the antibody is a polyclonal antibody claim 1 , a monoclonal antibody claim 1 , or a chimeric antibody.3. The method of claim 1 , wherein the antibody binds to the HLA-restricted antigen with a binding affinity of below 20 nanomolar.4. The method of claim 1 , wherein the antibody binds to the MHC class I molecule complexed with the HLA-restricted antigen.5. The method of claim 1 , wherein the antibody is humanized.6. The method of claim 1 , wherein the effective amount of the antibody is from about 1 μg/kg to about 100 mg/kg of body weight per day.7. The method of claim 1 , wherein the antibody is conjugated with a toxin.8pseudomonas. The method of claim 7 , wherein the toxin is selected from the group consisting of diptheria toxin claim 7 , exotoxin A claim 7 , ...

Подробнее
15-01-2015 дата публикации

MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS

Номер: US20150017251A1
Принадлежит: NOVARTIS AG

Immunogenic compositions are disclosed which comprise microparticles that comprise a biodegradable polymer, an immunological adjuvant and a tocol-family compound. Methods of making and using such microparticle compositions are also disclosed. 1. A composition comprising microparticles that comprise a biodegradable polymer , an immunological adjuvant and a tocol-family compound.2. The composition of claim 1 , wherein the immunological adjuvant is selected from imidazoquinoline compounds claim 1 , immunostimulatory oligonucleotides claim 1 , loxoribine claim 1 , bropirimine claim 1 , bacterial lipopolysaccharides claim 1 , peptidoglycan claim 1 , bacterial lipoproteins claim 1 , bacterial flagellins claim 1 , single-stranded RNA claim 1 , double-stranded RNA claim 1 , saponins claim 1 , lipotechoic acid claim 1 , ADP-ribosylating toxins and detoxified derivatives thereof claim 1 , polyphosphazene claim 1 , muramyl peptides claim 1 , thiosemicarbazone compounds claim 1 , tryptanthrin compounds claim 1 , and lipid A derivatives claim 1 , benzonaphthyridine compounds claim 1 , and lipopeptides.3. The composition of claim 1 , wherein the immunological adjuvant is an activator of Toll-like receptor 7 (TLR 7) or Toll-like receptor 8 (TLR8).46-. (canceled)7. The composition of claim 1 , wherein the immunological adjuvant is provided in an amount ranging from 0.1 to 20% w/w relative to the amount of biodegradable polymer in the microparticles.9. The composition of claim 8 , wherein at least one of R claim 8 , R claim 8 , Rand Ris —OH and at least one of R claim 8 , R claim 8 , R claim 8 , and Ris —CH.10. (canceled)11. The composition of claim 1 , wherein the tocol-family compound is selected from the group consisting of alpha-tocopherol claim 1 , beta-tocopherol claim 1 , gamma-tocopherol claim 1 , delta-tocopherol claim 1 , alpha-tocotrienol claim 1 , beta-tocotrienol claim 1 , gamma-tocotrienol claim 1 , and delta-tocotrienol.12. The composition of claim 1 , wherein tocol- ...

Подробнее
21-01-2016 дата публикации

Glycotargeting therapeutics

Номер: US20160015821A1

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Подробнее
28-01-2016 дата публикации

TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES

Номер: US20160022650A1
Принадлежит: Selecta Biosciences, Inc.

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes. 1. A composition comprising:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen associated with an undesired CD8+ T cell immune response.229-. (canceled)30. A dosage form comprising the composition of .31. A method comprising administering the composition of to a subject.32. (canceled)33. A method comprising:administering to a subject a composition comprising:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen associated with an undesired CD8+ T cell immune response, wherein the composition is in an amount effective to reduce the undesired CD8+ T cell immune response to the antigen in the subject.3468-. (canceled)69. A method comprising:(i) producing a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) producing or obtaining MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen associated with an undesired CD8+ T cell immune response.7079-. (canceled)80. A composition of any one of for use in therapy or prophylaxis.81. (canceled)82. Use of the composition of for the manufacture of a medicament for use in a method of reducing an undesired CD8+ T cell immune response to an antigen in a subject claim 1 , the treatment or prophylaxis of allergy claim 1 , autoimmune disease claim 1 , inflammatory disease claim 1 , organ or tissue rejection or graft versus host disease.83. (canceled) This application is a continuation of U.S. patent application Ser. No. 13/457,999, filed Apr. 27, 2012, pending, which ...

Подробнее
24-01-2019 дата публикации

Nanoparticle compositions and methods for immunotherapy

Номер: US20190022215A1
Автор: Bruce MCCREEDY
Принадлежит: Neximmune Inc

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

Подробнее
04-02-2016 дата публикации

TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS

Номер: US20160030555A1
Принадлежит: Selecta Biosciences, Inc.

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. 1. A method comprising:(A) administering to a subject a composition that comprises:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen, wherein the composition is in an amount effective to generate antigen-specific CD8+ regulatory T cells in the subject; or(B) generating antigen-specific CD8+ regulatory T cells in a subject by administering a composition that comprises:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted of an antigen; or(C) administering to a subject a composition according to a protocol that was previously shown to generate antigen-specific CD8+ regulatory T cells in one or more test subjects;wherein the composition comprises:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen.240-. (canceled)41. A composition comprising isolated antigen-specific CD8+ regulatory T cells produced according to the method of .4243-. (canceled)44. A dosage form comprising the composition of .45. A method comprising:(i) producing a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) producing or obtaining MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen.4656-. (canceled)57. A composition of for use in therapy or prophylaxis.58. (canceled)59. Use of the composition of for the manufacture of a medicament for use in a method of generating antigen-specific CD8+ regulatory T ...

Подробнее
04-02-2016 дата публикации

Immunogenic Composition in Emulsion Form

Номер: US20160030586A1
Принадлежит:

The present invention relates to an immunogenic composition comprising a continuous aqueous phase and a dispersed phase as droplets and comprising: 5. The immunogenic composition according to claim 1 , wherein:the amphiphilic lipid is a phospholipid, and/or{'sub': 12', '14', '16, 'the solubilizing lipid consists of a mixture of saturated fatty acid glycerides including at least 10% by weight of Cfatty acids, at least 5% by weight of Cfatty acids, at least 5% by weight of Cfatty acids and at least 5% by weight of C18 fatty acids, and/or'}the co-surfactant is selected from polyethyleneglycol/phosphatidyl-ethanolamine conjugate compounds, fatty acid and polyethyleneglycol ethers, fatty acid and polyethyleneglycol esters and block copolymers of ethylene oxide and propylene oxide, and the polyalkoxylated chain of the co-surfactant comprises from 10 to 200 ethylene oxide/propylene oxide units.6. The immunogenic composition according to claim 1 , comprising an immunostimulating agent.7. The immunogenic composition according to claim 1 , comprising:a biological targeting ligand either grafted or not on the co-surfactant, and/oran agent of interest selected from an optical agent or a physical agent, and/ora cationic surfactant.8. The immunogenic composition according to claim 1 , for which the viscosity is more than 0.1 Pa·s.10. The preparation method according to claim 9 , comprising prior to the contacting of the premix emulsion and of the compound of formula (LII) in order to form the surfactant bearing an antigen of formula (I) claim 9 , a step for preparing the compound of formula (LII) by chemically modifying an antigen for grafting thereon the group G.12. A drug comprising immunogenic composition of .13. A method for introducing an immune response against an antigen claim 1 , comprising the administration of the immunogenic composition according to a patient in need thereof.14. A method for treating or preventing an infection claim 1 , a cancer claim 1 , an ...

Подробнее
11-02-2016 дата публикации

COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE INDUCTION TO FACTOR VIII REPLACEMENT THERAPIES IN SUBJECTS WITH HEMOPHILIA A

Номер: US20160038575A1
Принадлежит:

This disclosure relates to tolerance inducing peptide (TIP) derived from the amino acid reference locus (AARL) within a FVIII replacement product (FVIIIrp) based on the differences between the expression product of a subject's F8 gene (sFVIII) and the FVIIIrp to provide tolerance induction before, during, and/or after a FVIII replacement therapy in a subject suffering from Hemophila A. Methods of deriving, making, and using the TIP are also disclosed. In some embodiments, the TIP is associated with a nanoparticle, e.g., PLGA or PLGA-PEMA nanoparticle. 110.-. (canceled)11. A method of providing a tolerance inducing peptide (TIP) , the method comprising ,determining an amino acid reference locus (AARL) within a FVIII replacement product (FVIIIrp) by determining differences between protein sequences of an expression product of a subject's F8 gene (sFVIII) and the FVIIIrp, andproviding a TIP comprising the AARL of the FVIIIrp, amino acid residues upstream of the AARL corresponding with contiguous amino acid residues upstream of the AARL in the FVIIIrp and/or amino acid residues downstream from the AARL corresponding with contiguous amino acid residues downstream of the AARL FVIIIrp.12. (canceled)13. The method of claim 11 , wherein the TIP has a length of X amino acid residues corresponding with a contiguous portion of the FVIIIrp across 2X−1 amino acids including X−1 amino acid residues upstream and X−1 amino acid residues downstream from an amino acid of the AARL within the FVIIIrp.14. The method of claim 13 , wherein providing a TIP is performed by providing a set of TIPs claim 13 , with each TIP within the set of TIPs having a length of X unique amino acid residues and a first amino acid residue shifted one residue upstream in the FVIIIrp sequence with reference to the AARL and wherein the set of TIPs collectively overlaps a contiguous portion of the FVIIIrp sequence spanning a length of 2X−1 residues.1516.-. (canceled)1716. A composition comprising a TIP prepared ...

Подробнее
16-02-2017 дата публикации

BIODEGRADABLE NANOCOMPLEX

Номер: US20170043007A1
Автор: CHEN Yu-Hung, Lin Yee-Shin
Принадлежит:

The present invention relates to a biodegradable nanocomplex. The biodegradable nanocomplex comprises a first electrically charged substance, a charge-redistribution substance, a second electrically charged substance and a carried substance, for holding the carried substance inside. The first electrically charged substance and the carried substance have the same electrical polarity, and the biodegradable nanocomplex has a nonuniformally and positively charge distribution along a radial direction thereof. The nonuniformally and positively charge distribution comprises a first electrically charged portion having substantially electrical neutrality, a second electrically charged portion surrounding the first electrically charged portion, and a third electrically charged portion surrounding the second electrically charged portion, in which the third electrically charged portion comprises an outermost surface of the biodegradable nanocomplex, thereby modulating the carried substance towards the desired immune responses via the nonuniformally and positively charge distribution. 1. A biodegradable nanocomplex , comprising: a first electrically charged portion having a first volume charge density, wherein the first volume charge density is substantially neutral;', 'a second electrically charged portion surrounding the first electrically charged portion; and', 'a third electrically charged portion surrounding the second electrically charged portion, wherein the third electrically charged portion comprises an outermost surface of the biodegradable nanocomplex., 'a first electrically charged substance, a charge-redistribution substance, a second electrically charged substance and a carried substance, for holding the carried substance inside, wherein the first electrically charged substance and the carried substance have the same electrical polarity, and the biodegradable nanocomplex has a nonuniformally and positively charge distribution along a radial direction thereof, and ...

Подробнее
15-02-2018 дата публикации

DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS

Номер: US20180043023A1
Принадлежит: Selecta Biosciences, Inc.

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods. 1. A method comprising:providing a dose of adjuvant and a dose of antigen, wherein at least a portion of the dose of adjuvant is coupled to synthetic nanocarriers,generating an antibody titer against the antigen through administration of the dose of adjuvant and the dose of antigen to a subject, andchoosing the dose of adjuvant to be less than a separate dose of adjuvant that results in an antibody titer similar to that generated through administration of the dose of adjuvant and the dose of antigen to the subject.216.-. (canceled)17. The method of claim 1 , wherein the synthetic nanocarriers comprise one or more polymers.18. (canceled)19. The method of claim 17 , wherein the one or more polymers comprise or further comprise a polyester coupled to a hydrophilic polymer.20. (canceled)21. The method of claim 19 , wherein the hydrophilic polymer comprises a polyether.22. (canceled)2325.-. (canceled)26. The method of claim 1 , wherein the subject has cancer claim 1 , an infectious disease claim 1 , a non-autoimmune metabolic disease claim 1 , a degenerative disease claim 1 , an addiction claim 1 , and atopic condition claim 1 , asthma; chronic obstructive pulmonary disease (COPD) or a chronic infection.27. (canceled)28. A method comprising:providing a dose of adjuvant, wherein at least a portion of the dose of adjuvant is coupled to synthetic nanocarriers,generating a systemic cytokine release through administration of the dose of adjuvant to a subject, andchoosing the dose of adjuvant to be greater than a separate dose of adjuvant that results in a systemic cytokine release similar to that generated through administration of the dose of adjuvant to the subject.29. The method of claim 28 , wherein the adjuvant comprises an agonist for Toll-Like Receptors 3 claim 28 , 4 claim 28 , 5 claim 28 , 7 claim 28 , 8 claim 28 , or 9 or a combination thereof.3031.-. ( ...

Подробнее
15-02-2018 дата публикации

PRODUCTION METHOD FOR POLY(AMINO ACID)

Номер: US20180044472A1
Принадлежит:

The present invention relates to a graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof (e.g., a graft copolymer (γ-PGA-PAE) of poly(γ-glutamic acid) (γ-PGA) and phenylalanine ethyl ester (PAE)), an ionized graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof, nanoparticles containing the ionized graft copolymer, and a production method thereof. The nanoparticles acquired in this way are useful as an adjuvant for producing a vaccine. 2. The ionized graft copolymer according to claim 1 , wherein the mole fraction x of the monomer unit represented by Formula (III) is 0.3. The ionized graft copolymer according to claim 1 , wherein n is 50 to 10 claim 1 ,000.4. The ionized graft copolymer according to claim 1 , wherein the ionized graft copolymer has a hydrophobic parameter K of −15 claim 1 ,000 to 0.5. A production method of an ionized graft copolymer of claim 1 , wherein the graft copolymer comprises of poly(amino acid) selected from the group consisting of poly(γ-glutamic acid) claim 1 , poly(α-glutamic acid) claim 1 , and poly(aspartic acid) claim 1 , or a salt thereof claim 1 , and a hydrophobic primary amine compound represented by Formula (I): A-NHor a salt thereof claim 1 , wherein A denotes a hydrophobic moiety claim 1 , the method comprising the step of:ionizing the graft copolymer by allowing a hydroxide of alkali metal, a carbonate of alkali metal, a hydrogencarbonate of alkali metal, a phosphate of alkali metal, a monohydrogen phosphate of alkali metal, a dihydrogen phosphate of alkali metal, an organic acid salt of alkali metal, or an acidic amino-acid salt of alkali metal to act on the graft copolymer of the poly(amino acid) or a salt thereof and the hydrophobic primary amine compound or a salt thereof.6. A production method of nanoparticles containing an ionized graft copolymer of a poly(amino acid) selected from the group ...

Подробнее
14-02-2019 дата публикации

ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF

Номер: US20190046654A1
Принадлежит:

The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease. 2. The conjugate of claim 1 , wherein the albumin binding peptide is covalently linked to the immunomodulatory molecule claim 1 , or the albumin binding peptide is operatively coupled to the immunomodulatory molecule via a linker domain.3. (canceled)4. The conjugate of claim 2 , wherein the linker domain comprises a Gly-Ser linker or a polyethylene glycol (PEG) linker.5. The conjugate of claim 4 , wherein the Gly-Ser linker is a (GlySer)linker.6. The conjugate of claim 4 , wherein the PEG linker is a PEGlinker.7. The conjugate of claim 1 , wherein the immunomodulatory molecule is a peptide antigen or a molecular adjuvant.8. The conjugate of claim 7 , wherein the peptide antigen is a cancer antigen or a melanoma antigen.9. (canceled)10. The conjugate of claim 7 , wherein the molecular adjuvant is CpG DNA.11. The conjugate of claim 1 , wherein the albumin binding peptide comprises the amino acid sequence DICLPRWGCLW.12. A vaccine comprising the conjugate of and a pharmaceutically acceptable carrier or excipient.13. The vaccine of further comprising an adjuvant.15. The composition of claim 14 , wherein the conjugate exhibits increased accumulation in the lymph node when administered to the subject in vivo compared to administration of the antigen alone.16. An immunogenic composition comprising the conjugate of .17. An immunogenic composition comprising the vaccine of .18. A method for treating cancer or an infectious disease comprising administering to a subject an effective amount of the composition of to reduce one or more symptoms of the cancer or infectious disease compared to a control.19. A method for increasing an immune response in a subject comprising administering to the subject ...

Подробнее
21-02-2019 дата публикации

SYNERGISTIC TUMOR TREATMENT WITH IL-2, AN INTEGRIN-BINDING-FC FUSION PROTEIN, AND A CANCER VACCINE

Номер: US20190054145A1
Принадлежит:

The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types. 2. The method of claim 1 , wherein the IL-2 is an extended pharmacokinetic (PK) IL-2.3. The method of claim 2 , wherein the extended-PK IL-2 comprises a fusion protein.4. The method of claim 3 , wherein the fusion protein comprises an IL-2 moiety and a moiety selected from the group consisting of an immunoglobulin fragment claim 3 , serum albumin claim 3 , transferrin claim 3 , and Fn3 claim 3 , or variants thereof.5. The method of or claim 3 , wherein the IL-2 or extended-PK IL-2 comprises an IL-2 moiety conjugated to a non-protein polymer.6. The method of claim 5 , wherein the non-protein polymer is polyethylene glycol.7. The method of claim 4 , wherein the fusion protein comprises an IL-2 moiety operably linked to an immunoglobulin Fc domain.8. The method of claim 4 , wherein the fusion protein comprises an IL-2 moiety operably linked to human serum albumin.9. The method of claim 1 , wherein the integrin-binding polypeptide binds to a tumor-associated integrin selected from the group consisting of αβ claim 1 , αβ claim 1 , and αβ claim 1 , or combination thereof.10. The method of claim 1 , wherein the integrin-binding polypeptide binds to αβ claim 1 , αβ claim 1 , and αβ.11. The method of claim 1 , wherein the knottin polypeptide scaffold comprises at least three cysteine disulfide linkages or crosslinked cysteine residues claim 1 , and wherein the integrin-binding loop is adjacent to cysteine residues of the knottin polypeptide scaffold.12. The method of claim 11 , wherein the integrin-binding loop comprises an RGD peptide sequence.13. The method of claim 11 , wherein the knottin polypeptide scaffold is derived from a knottin protein selected from the group consisting of EETI-II claim 11 , AgRP claim 11 , and ...

Подробнее
20-02-2020 дата публикации

PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE

Номер: US20200054741A1
Принадлежит:

The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject. 157-. (canceled)58. A peptide antigen conjugate comprising:a. a peptide antigen (A) and a hydrophobic molecule (H) wherein the hydrophobic molecule is a poly(amino acid) comprising between 3 to 300 amino acids of which 3 or more of the amino acids comprise an aromatic group; orb. a peptide antigen (A), a hydrophobic molecule (H), and a charged molecule (C) that comprises one or more functional groups that are charged at physiologic pH and wherein the peptide antigen conjugate has a net electrostatic charge greater than or equal to about +3 or less than or equal to about −3 in an aqueous buffer at a pH of about 7.4.5958. The peptide antigen conjugate of claim 58 , wherein the peptide antigen conjugate comprises a N-terminal extension (B1) that is linked to the N-terminus of the peptide antigen (A) and/or a C-terminal extension (B2) that is linked to the C-terminus of the peptide antigen (A) claim 58 , wherein the hydrophobic molecule (H) is linked to the peptide antigen (A) either directly or indirectly through the extension (B1 or B2) and/or a Linker (L); and claim 58 , wherein the charged molecule (C) of the peptide antigen conjugate of claim (b) is linked to the peptide antigen (A) either directly or indirectly through the extension B1 and/or B2 and/or the Linker (L).60. The peptide antigen conjugate of claim 59 , wherein the B1 and/or B2 extension(s) comprise a degradable peptide sequence.61. The peptide antigen conjugate of claim 59 , wherein the N-terminal extension (B1) comprises an enzyme degradable peptide sequence comprising:i. A single amino acid PN1 selected from glycine, valine, leucine or isoleucine;ii. A dipeptide, wherein PN1 is selected from glycine, valine, leucine or isoleucine; and PC2′ is selected ...

Подробнее
23-03-2017 дата публикации

Vaccination composition

Номер: US20170079918A1
Принадлежит: Cristal Delivery BV

The present invention is directed to vaccination composition comprising a particle comprising a polymer matrix incorporating an adjuvant and/or an antigen, to method of making them and use. Particularly, the present invention results in adjuvants and/or antigens, covalently entrapped in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the adjuvant and/or antigen are covalently bonded in or to the polymer carriers or polymeric devices.

Подробнее
25-03-2021 дата публикации

MULTIPLE SCLEROSIS ASSOCIATED AUTOANTIGENS, AND USE THEREOF IN THERAPY AND DIAGNOSIS

Номер: US20210087246A1
Принадлежит:

A tolerogenic composition for use in a method of treatment for multiple sclerosis (MS) in a MS patient exhibiting T-cell autoreactivity against an endogenous epitope corresponding to a T-cell epitope comprised in the amino-acid sequence of SEQ ID NO: 5, the composition comprising a therapeutic T-cell epitope comprising a sequence of 8 consecutive amino acid residues differing from a sub-sequence of SEQ ID NO: 5 by 0-2 residue substitutions, deletions and/or insertions, or the composition comprising a nucleic acid encoding said therapeutic T-cell epitope. A method for determining the degree of multiple sclerosis (MS) related autoimmunity in a test subject, comprising providing a test sample derived from the test subject comprising viable T-cells; quantitating antigen-specific activation of the T-cells of the test sample in vitro in response to a test antigen comprising a T-cell epitope, wherein said T-cell epitope is as the above therapeutic T-cell epitope above; and comparing the quantitated antigen-specific activation to a relevant reference to determine the degree of MS-related autoimmunity in the test subject. 191-. (canceled)92. A method of treatment for multiple sclerosis (MS) in a MS patient exhibiting T-cell autoreactivity against an endogenous epitope corresponding to a specific T-cell epitope comprised in the amino-acid sequence of SEQ ID NO: 5 ,comprising administering to the patient in a tolerogenic manner a composition, thus inducing T-cell tolerance towards said T-cell epitope in the patient, [ a. identical to a sub-sequence of SEQ ID NO: 5; or', 'b. differing from a sub-sequence of SEQ ID NO: 5 by no more than m residue substitutions, deletions and/or insertions;', 'wherein n is at least 8, and m is 0, 1 or 2;, 'a) a therapeutic T-cell epitope comprising a sequence of n consecutive amino acid residues being, a. identical to a sub-sequence of SEQ ID NO: 5; or', 'b. differing from a sub-sequence of SEQ ID NO: 5 by no more than m residue substitutions, ...

Подробнее
30-03-2017 дата публикации

Vaccination with immuno-isolated cells producing an immunomodulator

Номер: US20170087234A1
Автор: Nicolas Mach
Принадлежит: MAXIVAX SA

Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as GM-C SF (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents.

Подробнее
05-05-2022 дата публикации

METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN

Номер: US20220133883A1

The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen.

Подробнее
19-03-2020 дата публикации

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN

Номер: US20200085943A1
Принадлежит: CureVac AG

The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases. 1. A method of inducing an immune response to an antigen , the method comprising administering to a subject in need thereof a pharmaceutical composition comprising: a) a polymeric carrier comprising disulfide-crosslinked cationic peptides, as a carrier; and', 'b) at least one immunostimulatory RNA (isRNA) molecule as a cargo,, '(A) a polymeric carrier cargo complex, comprisingand a) an antigen from a pathogen associated with infectious disease;', 'b) an antigen associated with allergy or allergic disease;', 'c) an antigen associated with autoimmune disease; and', 'd) an antigen associated with a cancer or tumour disease., '(B) at least one protein or peptide antigen that is selected from the group consisting of2. The method of claim 1 , wherein component (B) is not covalently linked to component (A).3Bacillus anthracisMycobacterium tuberculosis.. The method of claim 1 , wherein said protein or peptide antigen is from a pathogen selected from the list consisting of: Rabies virus claim 1 , ...

Подробнее
12-05-2022 дата публикации

Compositions Comprising Apoptotic Signaling and Methods for Induction of Antigen-Specific Tolerance

Номер: US20220143160A1
Принадлежит:

The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to include antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions. 1. A composition for induction of antigen-specific tolerance comprising a carrier particle attached thereto an apoptotic signaling molecule and an antigenic peptide.2. The composition of claim 1 , wherein said composition induces antigen-specific tolerance in a subject.3. The composition of claim 1 , wherein the antigenic peptide is an autoimmune antigen claim 1 , a transplantation antigen or an allergen.4. The composition of claim 3 , wherein the antigenic peptide is myelin basic protein claim 3 , acetylcholine receptor claim 3 , endogenous antigen claim 3 , myelin oligodendrocyte glycoprotein claim 3 , pancreatic beta-cell antigen claim 3 , insulin claim 3 , glutamic acid decarboxylase (GAD) claim 3 , collagen type 11 claim 3 , human carticlage gp39 claim 3 , fp130-RAPS claim 3 , proteolipid protein claim 3 , fibrillarin claim 3 , small nucleolar protein claim 3 , thyroid stimulating factor receptor claim 3 , histones claim 3 , glycoprotein gp70 claim 3 , pyruvate dehydrogenase dehyrolipoamide acetyltransferase (PCD-E2) claim 3 , hair follicle antigen or human tropomyosin isoform 5.5. The composition of claim 1 , wherein the antigenic peptide is coupled to the carrier by a conjugate molecule.6. The composition of claim 5 , wherein the conjugate is ethylene carbodiimide (ECDI).7. The composition of claim 1 , wherein the apoptotic signaling molecule is annexin-1 claim 1 , annexin-5 claim 1 , phosphatidyl serine claim 1 , or milk fat globule-EGF-factor 8 (MFG-E8).8. The composition of claim 1 , wherein the apoptotic signaling molecule is Fas-ligand or TNF-alpha.9. The composition of ...

Подробнее
05-04-2018 дата публикации

HOLLOW SILICA NANOSPHERES AND METHODS OF MAKING SAME

Номер: US20180092987A1
Принадлежит:

The disclosure provide hollow nanospheres and methods of making and using the same. The methods and compositions of the disclosure are useful for drug delivery and gene transfer. 1. A hollow silica nanoparticle for imaging tissue , comprising:a shell structure including silica and having a hollow interior, wherein the shell structure is porous; anda biocompatible coating on an outer surface of the shell structure.2. The hollow silica nanoparticle of claim 1 , wherein the shell structure includes a spherical shape.3. The hollow silica nanoparticle of claim 1 , wherein the hollow silica nanoparticle includes a diameter in a range of 10 nm to 1000 nm.4. The hollow silica nanoparticle of claim 1 , wherein the shell structure includes a diameter in a range of 40 nm to 500 nm.5. The hollow silica nanoparticle of claim 1 , wherein the shell structure includes a thickness in a range of 3 nm to 5 nm.6. The hollow silica nanoparticle of claim 1 , wherein the shell structure is formed of a uniform silica material layer having a plurality of pores distributed over the shell structure.7. The hollow silica nanoparticle of claim 6 , wherein the shell structure is formed by deposition of a silica compound on a functionalized template particle that is removed to create the hollow interior within the uniform silica material layer claim 6 , wherein the uniform silica material layer is able to withstand collapsing upon itself upon removal of the template particle.8. The hollow silica nanoparticle of claim 1 , wherein the biocompatible coating includes phosphonate polyethylene glycol (PPEG).9. The hollow silica nanoparticle of claim 1 , further comprising:a fluorescent dye coupled to the shell structure.10. The hollow silica nanoparticle of claim 9 , wherein the hollow silica nanoparticle is configured to locate at a tissue in a region of a living subject's body and to produce a detectable optical signal responsive to light directed at the tissue based on fluorescence of the fluorescent ...

Подробнее
02-04-2020 дата публикации

COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE

Номер: US20200101146A1
Принадлежит:

Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided. 170.-. (canceled)7280.-. (canceled) The present application claims the benefit of priority to U.S. Provisional Patent Application No. 62/521,270, filed Jun. 16, 2017, the entirety of which is hereby incorporated by reference herein.A Sequence Listing submitted as an ASCII text file via EFS-Web is hereby incorporated by reference in accordance with 35 U.S.C. § 1.52(e). The name of the ASCII text file for the Sequence Listing is ANOK019WO_ST25.TXT, the date of creation of the ASCII text file is Jun. 6, 2018, and the size of the ASCII text file is 86 KB.Several embodiments disclosed herein pertain generally to pharmaceutically acceptable compositions for use in inducing immune tolerance to specific antigens of interest, methods of generating such compositions, and methods/uses of same for induction of antigen specific tolerance.The liver is involved in a variety of tolerogenic processes, for example development of tolerance to harmless non-self-antigens absorbed into the blood draining from the gut or to newly formed antigens resulting from hepatic metabolic activities, such antigens failing to induce an immune response in healthy individuals. Antigen-specific tolerance and cross-tolerance induction towards CD4+ and CD8+ T cells, respectively, has been attributed to liver sinusoidal endothelial cells (LSECs), which as MHC-I- and MHC-II-expressing blood vessel- ...

Подробнее
03-05-2018 дата публикации

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALLERGIC REACTIONS

Номер: US20180117143A1
Принадлежит:

The invention relates to a pharmaceutical composition made of one or more preparations and comprising a physiologically effective dose of at least one IL-4 and/or IL-13 inhibitor and at least one allergene, and a matrix, wherein at least the inhibitor is solved or embedded, or whereon at least the inhibitor is coated or adsorbed, wherein the matrix is selected as to enable prolonged release of the inhibitor. 1. A pharmaceutical composition made of one or more preparations and comprising a physiologically effective dose of at least one IL-4 and/or IL-13 inhibitor and at least one allergene , and a matrix , wherein at least the inhibitor is solved or embedded , or whereon at least the inhibitor is coated or adsorbed , wherein the matrix is selected as to enable prolonged release of the inhibitor.2. The composition according to claim 1 , wherein the inhibitor is selected from the group consisting of antagonistic IL-4 and/or IL-13 derivatives claim 1 , soluble cytokine receptor constructs with specificity for IL-4 and/or IL-13 and/or precursors thereof claim 1 , monoclonal antibodies specific for IL-4 and/or IL-13 and/or their precursors and/or their receptors claim 1 , binding fragments of such antibodies claim 1 , proteinaceous constructs with specificity for IL-4 and/or IL-13 and/or their precursors and/or their receptors claim 1 , and aptamers with specificity for IL-4 and/or IL-13 and/or their precursors and/or their receptors.3. The composition according to claim 1 , wherein at least two different inhibitors are comprised claim 1 , wherein at least one inhibitor inhibits IL-4 and at least one other inhibitor inhibits IL-13 claim 1 , or wherein at least one inhibitor is comprised claim 1 , which inhibits both claim 1 , IL-4 and IL-13.4. The composition according to claim 1 , wherein the inhibitor has a plasma half-life of less than 7 days claim 1 , preferably less than 1 day claim 1 , most preferably less than 6 or 5 hours.5. The composition according to claim 1 , ...

Подробнее
07-05-2015 дата публикации

Modular nanodevices for smart adaptable vaccines

Номер: US20150125384A1
Принадлежит: YALE UNIVERSITY

Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.

Подробнее
07-05-2015 дата публикации

Novel immunotherapy against several tumors including neuronal and brain tumors

Номер: US20150125478A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Подробнее
25-04-2019 дата публикации

MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES

Номер: US20190117793A1
Принадлежит:

Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system. 125.-. (canceled)26. A composition comprisingone or more antigens encapsulated in or incorporated into a polymeric nanoparticle that is surface modified with an adjuvant that is a bacterial or microbial derivative.27. The composition of claim 26 , wherein the bacterial or microbial derivative is selected from the group consisting of carbohydrates claim 26 , immunostimulatory oligonucleotides claim 26 , ADP-ribosylating toxins or detoxified derivatives thereof claim 26 , and combinations thereof.28. The composition of claim 26 , further comprising at least one protective layer claim 26 , wherein the protective layer is one which decreases particle degradation relative to a particle without a protective layer upon administration to a subject in need thereof.29. The composition of claim 27 , wherein the carbohydrates are or comprise lipopolysaccharide (LPS).30. The composition of claim 26 , wherein the bacterial or microbial derivative is or comprises a cell wall component of a gram negative bacteria.31. The protective layer of claim 28 , which is or comprises one or more of an enteric coating claim 28 , a physically-protective layer claim 28 , an environmentally-sensitive coating claim 28 , and a pH-responsive coating.32. The composition of claim 26 , wherein the one or more antigens are selected from the group consisting of viral claim 26 ...

Подробнее
25-04-2019 дата публикации

Modified biotin-binding protein, fusion proteins thereof and applications

Номер: US20190119335A1
Принадлежит: Childrens Medical Center Corp

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

Подробнее
12-05-2016 дата публикации

Compositions and methods for immunotherapy

Номер: US20160129133A1
Принадлежит: Nexlmmune Inc

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

Подробнее
01-09-2022 дата публикации

A METHOD OF ELICITING AN IMMUNE RESPONSE BY ADMINISTERING A POPULATION OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN TOGETHER WITH A POPULATION OF POLYMERSOMES HAVING AN ASSOCIATED ADJUVANT AS WELL AS COMPOSITIONS COMPRISING THE TWO POPULATIONS OF POLYMERSOMES

Номер: US20220273792A1
Принадлежит: ACM BIOLABS PTE LTD

The present invention relates to a method of eliciting an immune response in a subject by administration of an antigen and an adjuvant, wherein the antigen is associated with a first population of polymersomes, and wherein the adjuvant is associated with a second population of polymersomes, and wherein the two populations of polymersomes are administered to the subject. The present invention also relates to compositions such as vaccines comprising the two polymersome populations of the present invention, methods of eliciting an immune response or methods for treatment, amelioration, prophylaxis or diagnostics of a cancer, autoimmune or infectious disease, comprising providing polymersomes of the present invention. 1. A method of eliciting an immune response in a subject by administration of an antigen and an adjuvant , wherein the antigen is associated with a first population of polymersomes , and wherein the adjuvant is associated with a second population of polymersomes , and wherein the two populations of polymersomes are administered to the subject.2. The method of claim 1 ,(a) wherein the antigen is associated with the first population of polymersomes by encapsulation of the antigen within the first population of polymersomes, by integration of the antigen into the circumferential membrane of the polymersomes of the first population of polymersomes, by conjugation of the antigen to the exterior surface of the polymersomes via a covalent bond and/or by conjugation of the antigen to the exterior surface of the polymersomes via a non-covalent bond; and/or(b) the adjuvant is associated with the second population of polymersomes by encapsulation of the adjuvant within the second population of polymersomes, by integration of the adjuvant into the circumferential membrane of the polymersomes of the second population of polymersomes, by conjugation of the adjuvant to the exterior surface of the polymersome via a covalent bond and/or by conjugation of the adjuvant to ...

Подробнее
23-04-2020 дата публикации

A NOVEL TUMOR VACCINE AND USES THEREOF

Номер: US20200121770A1
Принадлежит:

The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve the problem in the art that no technical scheme is available for generating lasting and high-effective anti-tumor immune responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex is formed by nucleic acid, especially replicable nucleic acid not expressing exogenous gene, and cationic biomaterial. The nucleic acid and the cationic biomaterial in the tumor vaccine according to the present invention have synergistic interactions on direct killing of tumor cells, and induction of the innate immune response and adaptive immune response of body against tumor. In addition, the prepared tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application. 1. A tumor vaccine , comprising complex formed by DNA and cationic biomaterial , the DNA has a length of 50-10000 bp , and the cationic biomaterial is at least one of cationic lipid material or cationic polymer.2. The tumor vaccine according to claim 1 , characterized in that the DNA has a length of 100-6000 bp.3. The tumor vaccine according to claim 1 , characterized in that the DNA is linear DNA or circular DNA.4. The tumor vaccine according to claim 3 , characterized in that the linear DNA is mitochondrial DNA or mitochondrial DNA fragment.5. The tumor vaccine according to claim 3 , characterized in that the circular DNA is plasmid.6. The tumor vaccine according to claim 5 , characterized in that the plasmid is selected from at least one of pMVA claim 5 , pMVA-1 claim 5 , pVAX1 claim 5 , pcDNA3.1 claim 5 , pBR322 claim 5 , and pUC18.7. The tumor vaccine according to claim 5 , characterized in that the plasmid is a replicable plasmid which comprises a replicon claim 5 , a resistance gene and a plasmid backbone sequence but is unable to express an ...

Подробнее
19-05-2016 дата публикации

Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent

Номер: US20160136288A1
Принадлежит:

The application relates to an immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 as droplets, wherein the dispersed phase 1 comprises a surfactant 1 bearing an antigen and the dispersed phase 2 comprises an immunostimulating agent 2, to its preparation method and its uses, notably for producing antibodies, as a drug, as a vaccine or in an immunization method. 1. An immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 as droplets wherein: an amphiphilic lipid 1,', 'a solubilizing lipid 1 comprising at least one fatty acid glyceride,', 'a co-surfactant 1 comprising at least one chain consisting of alkylene oxide units,', {'br': None, 'sub': 1', '1', '1', '1', 'v', '1, '(L-X-H-Y)-G-Z-Ag \u2003\u2003(I),'}, 'a surfactant 1 bearing an antigen of the following formula (I)], 'the dispersed phase 1 comprises [{'sub': '1', 'Lrepresents a lipophilic group,'}, {'sub': 1', '1', '1, 'X, Y, Zand G represent independently a binding group,'}, {'sub': '1', 'Hrepresents a hydrophilic group comprising a polyalkoxylated chain,'}, 'v is an integer from 1 to 8, and', 'Ag represents an antigen,, 'whereinwherein the molar ratio of the surfactant 1 bearing an antigen of formula (I) over the sum of the co-surfactant 1 and of the surfactant 1 bearing an antigen of formula (I) is from 0.01% to 5%, and an amphiphilic lipid 2,', 'a solubilizing lipid 2 comprising at least one fatty acid glyceride,', 'a co-surfactant 2 comprising at least one chain consisting of alkylene oxide units,', 'an immunostimulating agent 2,, 'the dispersed phase 2 compriseswith the proviso that the dispersed phase 2 is free of surfactant bearing an antigen of formula (I).5. The immunogenic composition according to claim 1 , wherein:the amphiphilic lipid 1 and/or the amphiphilic lipid 2 is(are) a phospholipid, and/or{'sub': 12', '14', '16, 'the solubilizing lipid 1 and/or the solubilizing lipid 2 consist(s) of a mixture ...

Подробнее
08-09-2022 дата публикации

Methods for lowering the infection rate of viruses

Номер: US20220280439A1
Автор: Erik Johan NIEMELÄ
Принадлежит: Finncure Oy

According to some embodiments, a method of reducing a likelihood of a pathogen binding to cell structures of a host comprises at least partially blocking the pathogen from binding to cell structures of the host as a result of competitive inhibition by delivering a carrier to the host, and at least partially reducing the likelihood of the pathogen binding to target areas of cell structures of the host.

Подробнее
08-09-2022 дата публикации

Brush polymers for therapeutic applications

Номер: US20220280625A1
Принадлежит: Northwestern University

In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides as side chain moieties. Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers and brush block copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers.

Подробнее
30-04-2020 дата публикации

Glycotargeting therapeutics

Номер: US20200129601A1

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Подробнее
10-06-2021 дата публикации

PATHOGEN VACCINES AND METHODS OF PRODUCING AND USING THE SAME

Номер: US20210170007A1
Принадлежит:

The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein. 1. A vaccine composition , comprisingan opsonin-bound or lectin-bound pathogen construct, and a bioagent capable of recruiting an immune cell in a subject.258-. (canceled)59. A method of treating a pathogen infection in a subject in need thereof claim 1 , comprising administering the vaccine composition of to the subject claim 1 , thereby treating the pathogen infection in the subject.60. A method of vaccinating a subject against a pathogen infection claim 1 , comprising administering the vaccine composition of to the subject claim 1 , thereby vaccinating the subject against the pathogen infection.61. A method of treating an antibiotic-resistant bacterial infection in a subject in need thereof claim 1 , comprising administering the vaccine composition of to the subject claim 1 , thereby treating the antibiotic-resistant bacterial infection in the subject.62. (canceled)63. A method of decreasing the level of a pathogen in a subject having a pathogen infection claim 1 , comprising administering the vaccine composition of to the subject claim 1 , thereby decreasing the level of the pathogen in the subject. ...

Подробнее
14-05-2020 дата публикации

HYDROGEL DELIVERY OF STING IMMUNOTHERAPY FOR TREATMENT CANCER

Номер: US20200146975A1
Принадлежит:

In one aspect, the present disclosure provides for novel compositions of matter comprising multi domain peptide (MDP) hydrogels and cyclic dinucleotides (CDNs). Also disclosed are method of using such compositions in the treatment of cancer, including in particular the treatment of head and neck cancers, such as those resistant to CDN therapy. 1. A composition comprising (a) a multi-domain peptide (MDP) hydrogel and (b) a cyclic dinucleotide (CDN).2. The composition of claim 1 , wherein the CDN is a natural endogenous CDN claim 1 , such as produced by cGAS.3. The composition of claim 1 , wherein the CDN is a synthetic CDN claim 1 , such as CDN analog.4. The composition of claim 3 , wherein the CDN analog comprises a modified base or non-natural internucleoside linkage.5. The composition of claim 1 , the CDN is dithio-(R claim 1 ,R)-[cyclic[A(2′ claim 1 ,5′)pA(3′ claim 1 ,5′)p]] claim 1 , 2′2′-cGAMP claim 1 , 2′3′-cGAMP claim 1 , 3′3′-cGAMP claim 1 , c-di-AMP claim 1 , 2′3′-c-di-AMP claim 1 , 2′3′-c-di-AM(PS)2 claim 1 , c-di-GMP claim 1 , c-di-UMP claim 1 , c-di-IMP.6. The composition of claim 1 , wherein peptides of MDP hydrogel are 18-30 residues in length.7. The composition of claim 1 , wherein peptides of the MDP hydrogel have about a 3:1 ratio of hydrophilic to hydrophobic charged residues.8. The composition of claim 1 , wherein the peptides of the MDP hydrogel contain a bio-mimetic sequence.9. The composition of claim 1 , wherein the MDP hydrogel comprises a degradable sequence containing a tumor specific peptide.10. The composition of claim 1 , wherein the MDP hydrogel and the CDN are covalently or non-covalently bound to each other.11. A method of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a composition according to any one of .12. The method of claim 11 , wherein the cancer is a carcinoma claim 11 , sarcoma claim 11 , lymphoma claim 11 , leukemia claim 11 , melanoma claim 11 , mesothelioma claim ...

Подробнее
16-06-2016 дата публикации

COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE

Номер: US20160166664A1
Принадлежит: Northwestern University

The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions. 1. A composition for induction of antigen-specific tolerance comprising a carrier particle attached thereto an apoptotic signaling molecule and an antigenic peptide.2. (canceled)3. The composition of claim 1 , wherein the antigenic peptide is an autoimmune antigen claim 1 , a transplantation antigen or an allergen.4. The composition of claim 3 , wherein the antigenic peptide is myelin basic protein claim 3 , acetylcholine receptor claim 3 , endogenous antigen claim 3 , myelin oligodendrocyte glycoprotein claim 3 , pancreatic beta-cell antigen claim 3 , insulin claim 3 , glutamic acid decarboxylase (GAD) claim 3 , collagen type 11 claim 3 , human carticlage gp39 claim 3 , fp130-RAPS claim 3 , proteolipid protein claim 3 , fibrillarin claim 3 , small nucleolar protein claim 3 , thyroid stimulating factor receptor claim 3 , histones claim 3 , glycoprotein gp70 claim 3 , pyruvate dehydrogenase dehyrolipoamide acetyltransferase (PCD-E2) claim 3 , hair follicle antigen or human tropomyosin isoform 5.5. The composition of claim 1 , wherein the antigenic peptide is coupled to the carrier by a conjugate molecule.6. The composition of claim 5 , wherein the conjugate is ethylene carbodiimide (ECDI).7. The composition of claim 1 , wherein the apoptotic signaling molecule is annexin-1 claim 1 , annexin-5 claim 1 , phosphatidyl serine claim 1 , milk fat globule-EGF-factor 8 (MFG-E8) claim 1 , Fas-ligand or TNFalpha.8. (canceled)9. The composition of claim 1 , wherein the antigenic peptide is fused to the apoptotic signaling molecule.10. The composition of claim 1 , wherein the carrier particle is a ...

Подробнее
25-06-2015 дата публикации

INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT

Номер: US20150174234A1
Автор: CONTORNI Mario
Принадлежит: NOVARTIS VACCINES AND DIAGNOSTICS SRL

Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg per influenza virus strain per ml. Components (i) and (ii) can be presented in kit form. 1. A process for making an adjuvanted influenza vaccine , comprising a step of mixing substantially equal volumes of (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen , wherein the concentration of hemagglutinin in component (ii) is more than 60 μg per influenza virus strain per ml.2. The process of claim 1 , where the volume of a unit dose of the vaccine is less than 0.5 ml.3. A process for making an adjuvanted influenza vaccine claim 1 , comprising a step of mixing substantially equal volumes of (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen claim 1 , wherein the volume of a unit dose of the vaccine is less than 0.5 ml.4. A process for making an adjuvanted influenza vaccine claim 1 , comprising the steps of: (a) mixing substantially equal volumes of (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen claim 1 , to give a bulk vaccine; and (b) removing at least one unit dose from the bulk vaccine claim 1 , where the volume of the unit dose is less than 0.5 ml.5. The process of claim 3 , where the concentration of hemagglutinin in component (ii) is ...

Подробнее
28-05-2020 дата публикации

Methods and Compositions for Inducing Protective Immunity

Номер: US20200164066A1
Принадлежит: UNIVERSITY OF SASKATCHEWAN

This application relates to compositions comprising one or more CpG oligodeoxynucleotides complexed to nanoparticles comprising a gemini surfactant and optionally a muco-adhesive polymer, which can be used for intrapulmonary delivery to induce immunity in feed animals, and the methods of making and uses thereof.

Подробнее
08-07-2021 дата публикации

Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response

Номер: US20210205443A1
Принадлежит:

Disclosed are compositions, kits, and methods for modulating an immune response. The compositions and kits include and the methods utilize carbohydrate-modified particles having an immune modulator attached at the surface of the particles. The carbohydrate-modified particles and particulate formulations comprising the carbohydrate-modified particles may be utilized for modulating an immune response in a subject. 1. Carbohydrate-modified particles , the particles comprising a biodegradable polymeric base material having an effective average diameter of 0.01-500 pm and a carbohydrate moiety that is an immune modulator covalently attached at the surface of the particles.2Pseudomonas aeruginosa. The particles of claim 1 , wherein the carbohydrate moiety is selected from a group consisting of Heparin disaccharide I-A claim 1 , Heparin disaccharide II-A claim 1 , Heparin disaccharide III-A claim 1 , Heparin disaccharide IV-A claim 1 , Heparin disaccharide IV-S claim 1 , Heparin unsaturated disaccharide I-H claim 1 , Heparin unsaturated disaccharide II-H claim 1 , Heparin unsaturated disaccharide II-H claim 1 , Heparin unsaturated disaccharide I-P claim 1 , Chondroitin disaccharide Adi-OS claim 1 , Chondroitin disaccharide Adi-45 claim 1 , Chondroitin disaccharide Adi-65 claim 1 , Chondroitin disaccharide ADi-diSB claim 1 , Chondroitin disaccharide ADi-diSE claim 1 , Chondroitin disaccharide ADi-triS claim 1 , Chondroitin disaccharide ADi-UA2S claim 1 , Neocarradecaose-41 claim 1 ,3 claim 1 ,5 claim 1 ,7 claim 1 ,9-penta-0-sulphate claim 1 , neocarrahexadecaose-41 claim 1 ,3 claim 1 ,5 claim 1 ,7 claim 1 ,9 claim 1 ,11 claim 1 ,13 claim 1 ,15-octa-0-sulfate claim 1 , GalNAcj31-4Gal (receptor for pili of ) claim 1 , Blood group B type 2 linear trisaccharide claim 1 , P1 Antigen claim 1 , Tn Antigen claim 1 , Sialyl-Lewis A claim 1 , Sialyl-Lewis X claim 1 , Sialyl-Lewis X j3-methyl glycoside claim 1 , Sulfo-Lewis A claim 1 , Sulfo-Lewis X claim 1 , al-2-Mannobiose claim 1 , ...

Подробнее
08-07-2021 дата публикации

Micromolded or 3-d printed pulsatile release vaccine formulations

Номер: US20210205444A1

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

Подробнее
05-07-2018 дата публикации

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME

Номер: US20180185469A1
Принадлежит:

Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject. 1. A composition comprising an inactivated porcine reproductive and respiratory syndrome virus (PRRSV) associated with a nanoparticle , and an adjuvant , wherein the concentration of PRRSV prior to inactivation is from about 1×10to about 1×10TCID.2. The composition of claim 1 , wherein the adjuvant is a choleratoxin B subunit.3E. coli. The composition of claim 1 , wherein the adjuvant is an heat labile mutant toxin.4. The composition of claim 1 , wherein the adjuvant is a pathogen-associated molecular pattern (PAMP).5. The composition of claim 1 , wherein the adjuvant is a liposome.6. The composition of claim 1 , wherein the adjuvant is a lipopolysaccharide (LPS).7. The composition of claim 1 , wherein the inactivated PRRSV is surface arrayed on the nanoparticle.8. The composition of claim 1 , wherein the adjuvant is a component of a bacterial cell wall.9. The composition of claim 1 , wherein the adjuvant is an endocytosed nucleic acid selected from double-stranded RNA (dsRNA) claim 1 , single-stranded DNA (ssDNA) claim 1 , and unmethylated CpG dinucleotide-containing DNA.10. The composition of claim 1 , wherein the adjuvant does not contain aluminum.11. The composition of claim 1 , wherein the adjuvant is selected from a water-in-oil emulsion claim 1 , oil-in-water emulsion claim 1 , and water-oil-water emulsion.12. The composition of claim 1 , wherein the adjuvant is a liposaccharide.13. The composition of claim 1 , wherein the adjuvant is a toll-like receptor agonist.14. The composition of claim 1 , wherein the inactivated PRRSV is inactivated by chemical means.15. The composition of claim 1 , wherein the mean size of the nanoparticle is from about 200 nanometers to about 500 nanometers.16. The composition of claim 1 , wherein the nanoparticle has a positive zeta potential.17. The composition of claim 1 , further ...

Подробнее
05-07-2018 дата публикации

CARRIER FOR USE IN DELIVERING DRUG, CONJUGATE, COMPOSITION COMPRISING SAME, AND METHOD FOR ADMINISTRATING SAME

Номер: US20180185501A1
Принадлежит:

The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand. 12-. (canceled)3. A method for administering a drug to a subject , comprising:lowering blood glucose level in the subject; and subsequentlyadministering a drug to the subject whose blood glucose level has been lowered and increasing blood glucose level in the subject,wherein the drug is included in a carrier having an outer surface modified with a GLUT1 ligand.4. The method of claim 3 , wherein the carrier is a vesicle claim 3 , and 10 to 40% by mol of a polymer constituting the vesicle is modified with the GLUT1 ligand.5. The method of claim 3 , wherein the carrier is a vesicle claim 3 , and 40 to 100% by mol of a polymer constituting the vesicle is modified with the GLUT1 ligand.6. The method of claim 3 , wherein the carrier is a vesicle having a diameter of 400 nm or smaller.7. The method of claim 3 , wherein the GLUT1 ligand is glucose.8. The method of claim 3 , wherein the drug is at least one selected from the group consisting of a biologically active substance claim 3 , an antibody claim 3 , a nucleic acid claim 3 , a biocompatible fluorescent dye claim 3 , and a contrast medium.9. The method of claim 3 , wherein the carrier is a conjugate of one molecule of the GLUT1 ligand and one molecule of a polymer claim 3 , and the conjugate is capable of forming a vesicle such that the GLUT1 ligand is exposed on a surface of the vesicle.10. The method ...

Подробнее
19-07-2018 дата публикации

Ileum-targeting, mucoadhesive thiolated hpmcp vaccine protein delivery agent

Номер: US20180200373A1

The present disclosure relates to a thiolated hydroxypropyl methylcellulose phthalate (T-HPMCP) drug delivery vehicle which is pH responsive and is loaded with either a protein drug or an antigen, to T-HPMCP microparticles, and to a production method for an ileum-specific, pH responsive, T-HPMCP drug delivery vehicle, the method including a step of loading a protein drug or an antigen onto the T-HPMCP microparticles. The T-HPMCP microparticles of the present disclosure are soluble in chlorinated methane because of the introduction of the thiol group, while a T-HPMCP drug delivery vehicle produced from the particles can efficiently effect in vivo delivery of the protein drug or antigen which is loaded thereon, since said vehicle is pH responsive such that the in vivo residence time is extended and the vehicle can act specifically on the ileum.

Подробнее
04-08-2016 дата публикации

Continuous Cell Programming Devices

Номер: US20160220668A1
Принадлежит:

The present invention comprises compositions, methods, and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer. 122.-. (canceled)23. A device comprising a scaffold composition , a tumor antigen , a recruitment composition , and a deployment composition , wherein said deployment composition comprises a TLR3 agonist.24. The device of claim 23 , wherein said TLR3 agonist comprises a nucleic acid.25. The device of claim 24 , wherein said nucleic acid comprises a synthetically produced nucleic acid.26. The device of claim 25 , wherein said synthetically produced nucleic acid comprises double-stranded RNA.27. The device of claim 26 , wherein said nucleic acid comprises poly I:C.28. The device of claim 23 , further comprising a dendritic cell attracted into the device after the device is introduced into a subject.29. The device of claim 28 , wherein the dendritic cell comprises a plasmacytoid dendritic cell.30. The device of claim 28 , wherein said dendritic cell is activated by the device.31. The device of claim 23 , wherein said recruitment composition comprises granulocyte macrophage colony stimulating factor (GM-CSF).32. The device of claim 23 , wherein the recruitment composition is encapsulated.33. The device of claim 32 , wherein the encapsulated recruitment composition comprises GM-CSF.34. The device of claim 32 , wherein a pulse of said recruitment composition is released from said device within 1-7 days after said device is introduced into a subject claim 32 , leaving a residual amount of said recruitment composition followed by slow release of residual amount over several weeks.35. The device of claim 34 , wherein said pulse comprises at least 50% of the amount of said recruitment composition associated with said device.36. The device of claim 34 , wherein said ...

Подробнее
02-08-2018 дата публикации

METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN

Номер: US20180214540A1
Принадлежит:

The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for immunogen. 120-. (canceled)21. A method of eliciting in a subject an immune response to a non-self immunogen , comprising administering to the subject a composition comprising a polymersome carrier having a circumferential membrane of an amphiphilic polymer and the non-self immunogen integrated into the circumferential membrane of the amphiphilic polymer of the polymersome carrier.22. The method of claim 21 , wherein administering comprises intradermal claim 21 , intraperitoneal claim 21 , subcutaneous claim 21 , intravenous claim 21 , or intramuscular claim 21 , or non-invasive administration.23. The method of claim 21 , wherein the membrane-associated protein is a transmembrane protein claim 21 , G protein-coupled receptor claim 21 , neurotransmitter receptor claim 21 , kinase claim 21 , porin claim 21 , ABC transporter claim 21 , ion transporter claim 21 , acetylcholine receptor claim 21 , or cell adhesion receptor.24. The method of claim 21 , wherein the immunogen is a synthetic lipid or a natural lipid.25. The method of claim 21 , wherein the amphiphilic polymer comprises a diblock or a triblock (A-B-A or A-B-C) copolymer.26. The method of claim 25 , wherein the amphiphilic polymer comprises at least one monomer unit of a carboxylic acid claim 25 , an amide claim 25 , an amine claim 25 , an alkylene claim 25 , a dialkylsiloxane claim 25 , an ether or an alkylene sulphide.27. The method f claim 26 , wherein the amphiphilic polymer is a polyether block selected from the group consisting of an oligo(oxyethylene) block claim 26 , a poly(oxyethylene) block claim 26 , an oligo(oxypropylene) block claim 26 , a poly(oxypropylene) block claim 26 , an oligo(oxybutylene) block and a poly(oxybutylene) block.28. The method of claim 27 , wherein the amphiphilic polymer is selected from the group consisting of poly(ethyl ...

Подробнее
02-08-2018 дата публикации

COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

Номер: US20180214564A1
Принадлежит:

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule. 1. A pharmaceutical composition comprising:polymeric PLGA-PEG particles having a size in the range of about 100 to 200 nm, a surface charge of about 0 to −20 mV, and from about 100 to 1500 protein ligands per particle, the protein ligands optionally coupled through a sulfhydryl-maleimide chemistry;a population of anti-CD28 antibody ligands;a population of HLA ligands;one or more antigenic peptides for presentation to T cells; anda pharmaceutically acceptable carrier for intravenous, intra-arterial, subcutaneous, intradermal, intralymphatic, or intra-tumoral administration.2. The pharmaceutical composition of claim 1 , wherein the particles are substantially spherical or about spherical.3. The pharmaceutical composition of or claim 1 , wherein the PLGA is a polymer of about 50% lactic acid (LA) and 50% glycolic acid (GA).4. The pharmaceutical composition of any one of to claim 1 , wherein the PLGA polymer has a molecular weight of from about 25K to about 35K claim 1 , and the PEG has a molecular weight of from about 3K to about 10K.5. The pharmaceutical composition of any one of to claim 1 , having from 400 to 1000 ligands per particle.6. The pharmaceutical composition of any one of to claim 1 , wherein the anti-CD28 antibody ligands comprise a human IGHV4-59 germline framework optionally having from 5 to 15 murine framework residues claim 1 , and a IGKV4-01 germline framework optionally having from 3 to 15 murine framework residues.7. The pharmaceutical composition of any one of to claim 1 , wherein the anti-CD28 ligand is an antigen-binding antibody fragment.8. The ...

Подробнее
02-07-2020 дата публикации

COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE

Номер: US20200206333A1
Принадлежит:

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse. 1. A composition capable of inducing an endogenous immune response to at least one leukemia antigen , comprisinga polymer scaffold comprising open interconnected pores,a dendritic cell activating factor,a dendritic cell recruitment factor, andat least one leukemia antigen.2. The composition of claim 1 , wherein the at least one leukemia antigen is Wilms' Tumor 1 protein (WT-1) or an antigenic fragment thereof.3. The composition of claim 1 , wherein the at least one leukemia antigen is leukemic bone marrow lysate.4. The composition of claim 1 , wherein the at least one leukemia antigen comprises WT-1 H-2Db peptide WT-1(RMFPNAPYL (SEQ ID NO: 1)).5. The composition of claim 1 , wherein the dendritic cell activating factor is CpG.6. The composition of claim 5 , wherein the dendritic cell activating factor is CpG 1826.7. The composition of claim 1 , wherein the dendritic cell recruitment factor is GM-CSF.8. The composition of claim 1 , wherein one or more of the dendritic cell activating factor claim 1 , dendritic cell recruitment factor claim 1 , and leukemia antigen are encapsulated by the polymer scaffold.9. The composition of claim 1 , wherein the polymer scaffold comprises polyethylene glycol (PEG) and alginate.10. The composition of claim 9 , wherein the polymer scaffold comprises a molar ratio of PEG to Alginate of about 1:4.11. The ...

Подробнее
12-08-2021 дата публикации

COMPOSITIONS AND METHODS CONCERNING IMMUNE TOLERANCE

Номер: US20210244812A1
Принадлежит:

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response. 2. The compound of claim 1 , wherein the moiety that specifically targets a mannose receptor is selected from the group consisting of α-linked mannose claim 1 , β-linked mannose claim 1 , substituted mannose claim 1 , mannose-6-phosphate claim 1 , N-acetyl mannosamine claim 1 , and mannan having β(1-4) claim 1 , α(1-6) claim 1 , α(1-2) claim 1 , and/or α(1-3) linkages.3. The compound of claim 1 , wherein Y is a linker resulting from reaction of at least one of a N-hydroxysuccinamidyl linker claim 1 , maleimide linker claim 1 , PEG linker claim 1 , vinylsulfone linker claim 1 , pyridyl di-thiol-poly(ethylene glycol) linker claim 1 , pyridyl di-thiol linker claim 1 , n-nitrophenyl carbonate linker claim 1 , NHS-ester linker claim 1 , and nitrophenoxy poly(ethylene glycol)ester linker.4. The compound of claim 3 , wherein Y is covalently bound to X.6. The compound of claim 1 , wherein Y is an antibody claim 1 , antibody fragment claim 1 , peptide or other ligand that binds to X.7. The compound of claim 1 , wherein X is an antigen against which a patient may develop or has developed an unwanted immune response.8. The compound of claim 7 , wherein the antigen is a foreign transplant antigen claim 7 , an alloantigen claim 7 , an autoimmune antigen claim 7 , a food antigen claim 7 , an animal antigen claim 7 , a plant antigen claim 7 , an environmental antigen claim 7 , a therapeutic antigen claim 7 , a synthetic self-antigen claim 7 , or a tolerogenic portion thereof.9. The compound of claim 8 , wherein X is an asparaginase antigen or an ovalbumin antigen.10. The compound of claim 1 , wherein the mannose receptor is mannose-6-phosphate receptor.11. The compound of claim 1 , wherein Y and X are connected through a bond ...

Подробнее
11-08-2016 дата публикации

PARTICLES WITH MULTIPLE FUNCTIONALIZED SURFACE DOMAINS

Номер: US20160228574A1
Принадлежит:

This disclosure relates to particles (e.g., nanoparticles and microparticles) that display multiple functionalized surface domains in a controlled mosaic pattern. The disclosure also provides simple methods to create various particles that have multiple functionalized surface domains while allowing the use of a wide variety of diverse core structures. The multiple functionalized domains provide controllable particle binding and orientation, and controlled and sustained drug release profiles. 145.-. (canceled)46. A method of delivering an agent to a subject , the method comprising (a) a core structure having a surface; a plurality of first linkers, each comprising a first end that binds to the surface of the core structure, and a second end that comprises a first functional group; and a plurality of second linkers, each comprising a first end that binds to the surface of the core structure, and a second end that comprises a second functional group, wherein the first and second functional groups are different wherein the linkers are bound to the surface of the core structure via their respective first ends, and wherein the first and second functional groups form an external mosaic of surface domains, a majority of each domain comprising one type of functional group, and', '(b) therapeutic, prophylactic, or diagnostic agents;', 'and, '(i) obtaining a composition comprising a plurality of particles having multiple functionalized surface domains, the particles comprising'}(ii) administering to the subject the composition.4749-. (canceled)50. The method of for imaging a region of a subject claim 46 , the method comprisingadministering the composition wherein the agent is a diagnostic agent; and detecting the the diagnostic agent.51. The method of for treating a disorder in a subject in need thereof claim 46 , the method comprising administering to the subject the composition wherein the agent is a therapeutic or prophylactic agent selected to treat the disorder.5258-. ( ...

Подробнее
23-10-2014 дата публикации

IMMUNOGENIC COMPLEXES OF POLYANIONIC CARBOMERS AND ENV POLYPEPTIDES AND METHODS OF MANUFACTURE AND USE THEREOF

Номер: US20140314703A1
Автор: Barnett Susan W., Dey Antu
Принадлежит:

The present invention relates to immunogenic complexes formed between polyanionic carbomers and Env polypeptides. Uses of the immunogenic complexes in applications including inducing an immune response and immunization generally are described. Methods of forming and manufacture of the immunogenic complexes are also described. The present invention also relates to immunogenic compositions including low viscosity, polyanionic carbomers and Env polypeptides. Uses of such immunogenic compositions in applications including inducing an immune response and immunization generally are described. Methods of manufacture of such immunogenic compositions are also described. 170-. (canceled)71. An injectable immunogenic composition comprising an Env polypeptide complexed to a polyanionic carbomer polymer.72. An immunogenic composition comprising an Env polypeptide complexed to a polyanionic carbomer polymer , wherein the concentration of the polyanionic carbomer polymer is between about 0.01% (w/v) and about 0.5% (w/v).73. The immunogenic composition of claim 71 , wherein the concentration of the polyanionic carbomer polymer is between about 0.01% (w/v) and about 0.5% (w/v).74. The immunogenic composition of claim 71 , wherein the polyanionic polymer comprises CARBOPOL 971P NF™ claim 71 , CARBOPOL 974P NF™ claim 71 , or combinations thereof.75. The immunogenic composition of claim 72 , wherein the polyanionic polymer comprises CARBOPOL 971P NF™ claim 72 , CARBOPOL 974P NF™ claim 72 , or combinations thereof.76. The immunogenic composition of claim 71 , wherein the Env polypeptide comprises a polypeptide selected from the group consisting of a gp160 Env polypeptide claim 71 , a polypeptide derived from a gp160 Env polypeptide claim 71 , a gp140 Env polypeptide claim 71 , a polypeptide derived from a gp140 Env polypeptide claim 71 , a gp120 Env polypeptide claim 71 , and a polypeptide derived from a gp120 Env polypeptide.77. The immunogenic composition of claim 71 , wherein the Env ...

Подробнее
18-07-2019 дата публикации

Recombinant eimeria maxima protein delivered as nanoparticles

Номер: US20190216911A1

Provided herein are immunogenic compositions containing recombinant proteins capable of presenting all, or antigenic portions of, the Eimeria maxima, Eimeria tenella, and Eimeria acervulina IMP1 protein in developing active immunity to, and control of, coccidiosis. Also provided are methodologies of using the immunogenic compositions for administration to poultry and other animals in the control of coccidiosis. Nanoparticle-conjugated rIMP1 immunogenic compositions and methods of making and using them are provided.

Подробнее
26-08-2021 дата публикации

Novel immunotherapy against several tumors including neuronal and brain tumors

Номер: US20210261614A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Подробнее
13-11-2014 дата публикации

Pharmaceutical composition for treatment of allergic reactions

Номер: US20140335162A1

The invention relates to a pharmaceutical composition made of one or more preparations and comprising a physiologically effective dose of at least one IL-4 and/or IL-13 inhibitor and at least one allergene, and a matrix, wherein at least the inhibitor is solved or embedded, or whereon at least the inhibitor is coated or adsorbed, wherein the matrix is selected as to enable prolonged release of the inhibitor.

Подробнее
08-09-2016 дата публикации

Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins

Номер: US20160256401A1
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

Подробнее
13-09-2018 дата публикации

IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS

Номер: US20180256709A1
Принадлежит: Selecta Biosciences, Inc.

This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner. 1122.-. (canceled)126. The compound of claim 125 , wherein:{'sub': '1', 'R═H, OH, ethoxymethyl;'}{'sub': '2', 'R=isobutyl, hydroxyisobutyl, methanesulfonamidoisobutyl, or benzyl;'}{'sub': 3', '4, 'Ris absent if Y═N; or is combined with Rto form a benzene ring with the carbon atoms of the pyridine ring to which they are connected if Y═C;'}{'sub': 4', '3', '3, 'Ris pentyl, butoxy, benzylamino, or butylamino when not combined with Rto form a benzene ring with the carbon atoms of the pyridine ring to which they are connected; or is combined with Rto form a benzene ring with the carbon atoms of the pyridine ring to which they are connected.'}127. A composition comprising the compound of .128. A synthetic nanocarrier that comprises the compound of .129. A composition comprising the synthetic nanocarrier of .130. A composition comprising a vaccine comprising the compound of .131. A method comprising:{'claim-ref': {'@idref': 'CLM-00123', 'claim 123'}, 'administering the compound of to a subject.'}133. The method of claim 132 , wherein:{'sub': '1', 'R═H, OH, ethoxymethyl;'}{'sub': '2', 'R=isobutyl, hydroxyisobutyl, methanesulfonamidoisobutyl, or benzyl;'}{'sub': 3', '4, 'Ris absent if Y═N; or is combined with Rto form a benzene ring with the carbon atoms of the pyridine ring to which they are connected if Y═C;'}{'sub': 4', '3', '3, 'Ris pentyl, butoxy, benzylamino, or butylamino when not combined with Rto form a benzene ring with the carbon atoms of the pyridine ring to which they are connected; or is combined with Rto form a benzene ring with the carbon atoms of the pyridine ring to which they are connected.'}135. The method of claim 134 , wherein:{'sub': '1', ' ...

Подробнее
06-08-2020 дата публикации

NANOPARTICLES FOR TREATMENT OF ALLERGY

Номер: US20200246445A1
Автор: Caplan Michael J.
Принадлежит:

The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions. In some embodiments, provided nanoparticles are associated with functional elements that cause the nanoparticles to mimic bacterial cells. The present invention encompasses the surprising finding that provided nanoparticles may be useful for treatment and/or prevention of multiple different allergies in a single patient. The present invention encompasses the recognition that provided empty nanoparticles may be useful as a “pan-allergy” therapeutic and/or vaccine. 117-. (canceled)18. A method of characterizing a preparation comprising a population of PLGA nanoparticles , which nanoparticles are substantially free of one or more allergens , the method comprising steps of:(i) assessing size distribution of nanoparticles in the preparation;(ii) assessing ability to suppress Th2 and/or increase Th1-type immune responses.19. The method of claim 18 , wherein the surfaces of the nanoparticles are associated with one or more modifications.20. The method of claim 19 , wherein the one or more modifications is or comprises a microbial mimic entity.21. The method of claim 20 , wherein the microbial mimic entity is or comprises a PAMP.22. The method of claim 21 , wherein the PAMP is one or both of LPS and flagellin.23. The method of claim 22 , wherein if both LPS and flagellin are present claim 22 , the ratio of LPS to flagellin is 9:1.24. The method of claim 23 , wherein LPS and flagellin may be present on the same or different nanoparticles in the population.25. The method of claim 19 , wherein the nanoparticles further comprise CpG claim 19 , and wherein the CpG is optionally encapsulated within the nanoparticles.26. The method of claim 22 , wherein the nanoparticles further comprise CpG claim 22 , and wherein the CpG is ...

Подробнее
22-09-2016 дата публикации

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

Номер: US20160271237A1
Автор: Santamaria Pedro
Принадлежит:

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as antipathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases. 1. A method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject a nanoparticle complex comprising antigen-MHC complexes operatively coupled to a non-liposomal nanoparticle core in an amount sufficient to expand anti-pathogenic autoreactive T cells; wherein the non-liposomal nanoparticle core has a diameter of less than 1 μm; and wherein the ratio of antigen-MHC complexes operatively coupled to the non-liposomal nanoparticle core is from about 10:1 to about 1000:1.2. The method of claim 1 , wherein the non-liposomal nanoparticle core further comprises an outer layer claim 1 , and wherein the antigen-MHC complexes are operatively coupled to the non-liposomal nanoparticle core or the outer layer.3. The method of claim 2 , wherein the outer layer comprises polyethylene glycol.4. The method of or claim 2 , wherein the non-liposomal nanoparticle core comprises a metal claim 2 , a metal oxide claim 2 , a metal sulfide claim 2 , a metal selenide claim 2 , a magnetic material claim 2 , or a polymer.5. The method of claim 4 , wherein the metal is gold or iron.6. The method of claim 4 , wherein the metal oxide is iron oxide.7. The method of or claim 4 , wherein the antigen is derived from an autoantigen claim 4 , an autoantigen epitope claim 4 , or a mimic thereof.8. The method of or claim 4 , wherein the antigen-MHC complexes comprise the same or different autoantigens or antigens.9. The ...

Подробнее
28-10-2021 дата публикации

ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF

Номер: US20210330800A1
Принадлежит:

The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease. 2. The method of claim 1 , wherein the immunomodulatory molecule further comprises a peptide antigen or an immunostimulatory oligonucleotide.3. The method of claim 1 , wherein the method further comprises administering multiple doses of the conjugate.4. The method of claim 1 , wherein the method further comprises administering the conjugate at various locations.5. The method of claim 1 , wherein the method further comprises administering the conjugate directly to a site in need of an immune response.6. The method of claim 1 , wherein the subject has cancer or an infectious disease. The method of claim 1 , wherein the albumin binding peptide is covalently linked to the immunomodulatory molecule claim 1 , or the albumin binding peptide is operatively coupled to the immunomodulatory molecule via a linker domain.87. The method of claim claim 1 , wherein the linker domain comprises a Gly-Ser linker or a polyethylene glycol (PEG) linker.9. The method of claim 8 , wherein the Gly-Ser linker is a (Gly4Ser)n (SEQ ID NO: 44) linker claim 8 , and wherein n is 1-6.10. The method of claim 8 , wherein the PEG linker is a PEGlinker.11. The method of claim 1 , wherein the immunomodulatory molecule comprises an immunomodulatory oligonucleotide.12. The method of claim 11 , wherein the immunomodulatory oligonucleotide is CpG DNA.13. The method of claim 1 , wherein the albumin binding peptide comprises the amino acid sequence DICLPRWGCLW (SEQ ID NO: 9).14. The method of claim 1 , wherein the immunomodulatory molecule is a peptide antigen.15. The method of claim 14 , wherein the peptide antigen is a cancer antigen or a melanoma antigen.16. The method of claim 14 , wherein the peptide antigen is a tumor- ...

Подробнее
04-11-2021 дата публикации

METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF

Номер: US20210340524A1
Принадлежит:

The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells. 1. A method for identifying a peptide ligand that selectively binds a chimeric antigen receptor (CAR) , wherein the method comprises:{'sup': '6', '(i) providing a cellular library comprising a population of cells that display at least 10unique variable peptides, wherein the variable peptides are 5 or more amino acid residues in length; and'}{'sub': 'D', '(ii) selecting a peptide sequence motif that binds the CAR antigen-recognition domain with a binding affinity (K) of at least 5 μM.'}2. The method of claim 1 , wherein providing the cellular library comprises (i) transforming a population of cells with a library of vectors claim 1 , wherein each vector comprises a synthetic polynucleotide that encodes a variable peptide operably-linked to an adhesion protein claim 1 , and (ii) maintaining the population of cells under conditions that induce expression of the synthetic polynucleotide in a plurality of transformed cells claim 1 , wherein the cellular library is a phage display library claim 1 , a viral display library claim 1 , a yeast display library claim 1 , a bacterial display library claim 1 , a mammalian cell display library claim 1 , or an insect cell display library.3. (canceled)4. The method of claim 2 , wherein (i) the synthetic polynucleotide encodes a variable peptide that is at least 5 claim 2 , 6 claim 2 , 7 claim 2 , 8 claim 2 , 9 claim 2 , 10 claim 2 , 11 claim 2 , 12 claim 2 , 13 claim 2 , 14 claim 2 , 15 claim 2 , 16 claim 2 , 17 claim 2 , 18 claim 2 , 19 claim 2 , or 20 amino acid residues in length claim 2 , and wherein each amino acid residue of the variable peptide is encoded by a degenerate codon; or{'sub': 'w', '(ii) wherein the ...

Подробнее
29-09-2016 дата публикации

Tolerogenic synthetic nanocarriers for allergy therapy

Номер: US20160279234A1
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.

Подробнее
29-08-2019 дата публикации

Peptide Conjugated Particles

Номер: US20190262441A1
Принадлежит:

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). 1. A composition comprising: an antigen coupled to a carrier particle with a negative zeta potential.24-. (canceled)5. The composition of claim 1 , wherein the particle is a polystyrene particle claim 1 , a carboxylated polysterene particle claim 1 , or a poly(lactic-co-glycolic acid) particle.612-. (canceled)13. The composition of claim 1 , wherein said antigen comprises an autoimmune antigen claim 1 , an antigen expressed on a tissue to be transplanted into a subject claim 1 , or an allergen.1417-. (canceled)18. The composition of claim 1 , wherein said particle is biodegradable.19. The composition of claim 1 , wherein said particle is surface functionalized.20. The composition of claim 19 , wherein said particle is carboxylate surface functionalized.21. The composition of further comprising a pharmaceutically acceptable carrier.22. A method of inducing antigen-specific tolerance in a subject comprising: administering to said subject claim 1 , an effective amount of a composition comprising an antigen-coupled particle to said subject claim 1 , wherein said particle has a negative zeta potential.23. The method of claim 22 , wherein said administering is performed to treat or prevent a disease or condition.24. The method of claim 23 , wherein said disease or condition is selected from the group consisting of: an autoimmune disease claim 23 , inflammatory disease claim 23 , an allergy claim 23 , transplantation rejection claim 23 , and a hyperimmune response.25. (canceled)26. The method of claim 22 , wherein the particle is a polystyrene particle claim 22 , a carboxylated polysterene particle claim 22 , or a poly(lactic-co-glycolic acid) particle. ...

Подробнее
22-10-2015 дата публикации

METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN

Номер: US20150297711A1
Принадлежит:

The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen. 1. A method for eliciting in a subject an immune response to an immunogen , comprising injecting the subject with a composition comprising a polymersome carrier having a circumferential membrane of an amphiphilic polymer and an immunogen integrated into the circumferential membrane of the amphiphilic polymer of the polymersome carrier , wherein the immunogen is a membrane-associated protein or lipid antigen.2. The method of claim 1 , wherein the injecting comprises intradermal claim 1 , intraperitoneal claim 1 , subcutaneous claim 1 , intravenous claim 1 , or intramuscular claim 1 , or non-invasive administration.3. The method of claim 1 , wherein the membrane-associated protein is a transmembrane protein claim 1 , G protein-coupled receptor claim 1 , neurotransmitter receptor claim 1 , kinase claim 1 , porin claim 1 , ABC transporter claim 1 , ion transporter claim 1 , acetylcholine receptor claim 1 , or cell adhesion receptor.4. The method of claim 1 , wherein the immunogen is a synthetic lipid.5. The method of claim 1 , wherein the immunogen is a natural lipid.6. The method of claim 1 , wherein the amphiphilic polymer comprises a diblock or a triblock (A-B-A or A-B-C) copolymer.7. The method of claim 6 , wherein the amphiphilic polymer comprises at least one monomer unit of a carboxylic acid claim 6 , an amide claim 6 , an amine claim 6 , an alkylene claim 6 , a dialkylsiloxane claim 6 , an ether or an alkylene sulphide.8. The method of claim 7 , wherein the amphiphilic polymer is a polyether block selected from the group consisting of an oligo(oxyethylene) block claim 7 , a poly(oxyethylene) block claim 7 , an oligo(oxypropylene) block claim 7 , a poly(oxypropylene) block claim 7 , an oligo(oxybutylene) block and a poly(oxybutylene) block.9. The method of claim 8 , wherein the amphiphilic polymer ...

Подробнее
22-10-2015 дата публикации

THERAPEUTIC AND VACCINE POLYELECTROLYTE NANOPARTICLE COMPOSITIONS

Номер: US20150297750A1
Принадлежит:

Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine. 1. A nanoparticle comprising:a first polyvalent carrier domain wherein the first polyvalent carrier domain is made up of more positively ionizable moieties than negatively ionizable moieties,a second polyvalent carrier domain wherein the second polyvalent carrier domain is made up of more negatively ionizable moieties than positively ionizable moieties,and an ionizable biologically active agent associated with the carrier.2. The nanoparticle of wherein the first and second polyvalent carrier domains are attached covalently to one another thereby providing both domains in the same molecule.3. The nanoparticle of wherein the first and second polyvalent carrier domains are present on two separate molecules.47-. (canceled)8. The nanoparticle of wherein the first or second polyvalent carrier domain comprises a polymer selected from the group consisting of a polyamide claim 1 , a polysaccharide claim 1 , a polyacetal claim 1 , and a polyester.9. The nanoparticle of wherein the first or second polyvalent carrier domain comprises multivalent cationic ionizable moieties selected from the group consisting of a polyamine claim 1 , a polyallylamine claim 1 , a polyimine claim 1 , a ...

Подробнее
03-09-2020 дата публикации

Method of making a personalized cancer vaccine

Номер: US20200276288A1
Принадлежит: Flow Pharma Inc

A method of making a personalized cancer vaccine is disclosed. The method includes predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. The predicting step can be implemented using artificial intelligence, statistical modeling, or a combination thereof. Particles are created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a biocompatible material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.

Подробнее
11-10-2018 дата публикации

Controlled Delivery of TLR Agonists in Structural Polymeric Devices

Номер: US20180289789A1
Принадлежит:

The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents. 1. A device comprising a porous polymeric structure composition , a disease-associated antigen , and a toll-like receptor (TLR) agonist , wherein said TLR agonist preferentially binds to TLR3.2. The device of claim 1 , wherein said disease-associated antigen comprises a tumor antigen.3. The device of claim 1 , wherein said polymeric structure composition comprises poly-lactide-co-glycolide (PLG).4. The device of claim 1 , wherein said TLR agonist comprises a TLR3 agonist.5. The device of claim 1 , wherein said TLR3 agonist comprises polyinosine-polycytidylic acid (poly I:C) or PEI-poly (I:C).6. The device of claim 1 , wherein said TLR agonist further comprises pathogen associated molecular patterns (PAMPs).7. The device of claim 1 , wherein said TLR agonist comprises a nucleic acid.8. The device of claim 1 , wherein said TLR agonist further comprises a TLR9 agonist.9. The device of claim 8 , wherein said TLR9 agonist comprises a cytosine-guanosine oligonucleotide (CpG-ODN) or a PEI-CpG-ODN.10. The device of claim 1 , wherein said device further comprises a recruitment composition.11. The device of claim 11 , wherein said recruitment composition comprises granulocyte macrophage colony stimulating factor (GM-CSF) claim 11 , Flt3L claim 11 , or CCL20.12. The device of claim 10 , wherein said recruitment composition comprises encapsulated GM-CSF.13. The device of claim 2 , wherein said tumor antigen comprises a tumor lysate claim 2 , purified protein tumor antigen claim 2 , or synthesized tumor antigen.14. The device of claim 6 , wherein said PAMPs comprises a monophosphoryl lipid A (MPLA).15. The device of claim 1 , wherein said device comprises a combination of TLR agonists claim 1 , said combination ...

Подробнее
26-10-2017 дата публикации

POLYMER ADJUVANT

Номер: US20170304420A1
Принадлежит:

The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant. 1. An adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to linear or branched unimolecular polymer chains that are capable of undergoing particle formation in aqueous conditions , or in aqueous conditions in response to external stimuli.2. The adjuvant according to claim 1 , wherein the polymer is a thermo-responsive polymer.3. The adjuvant according to or claim 1 , wherein the adjuvant is capable of assembling into particles in response to a temperature shift.4. The adjuvant according to any receding claim claim 1 , wherein the particles are a size capable of being phagocytosed claim 1 , or larger.5. The adjuvant according to any preceding claim claim 1 , wherein the adjuvant is capable of assembling into particles of sizes between about 20 nm and about 10 claim 1 ,000 nm.6. The adjuvant according to any preceding claim claim 1 , wherein the adjuvant is for local administration to a specific tissue claim 1 , site claim 1 , or region of the body.7. The adjuvant according to any preceding claim claim 1 , wherein the adjuvant is capable of being substantially retained in the body at the site of administration.8. The adjuvant according to any of to claim 1 , wherein the thermo-responsive polymer has a lower critical solution temperature (LCST) of≦40° C.9. The adjuvant according to any of to claim 1 , wherein the thermo-responsive polymer is responsive to a temperature shift from below body temperature to body temperature.10. The adjuvant according to any of to claim 1 , wherein the thermo-responsive polymer has a lower critical solution temperature of between 24° C. and 36° C.11. The adjuvant according to any of to ...

Подробнее
24-09-2020 дата публикации

NANOPARTICLE COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

Номер: US20200297843A1
Автор: McCreedy Bruce
Принадлежит:

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule. 144-. (canceled)45. An artificial antigen presenting cell (aAPC) comprising a polymeric nanoparticle having attached polypeptide ligands suitable for activating antigen-specific T cells , the nanoparticle having a size in the range of 20 to 200 nm , the nanoparticle comprising:a poly(lactic-co-glycolic acid) PLGA polymer core, anda hydrophilic shell formed of polyethylene glycol (PEG),wherein the polymeric nanoparticle comprises PLGA-PEG and PLGA-methoxyPEG (PLGA-mPEG) block co-polymers with the PLGA portion having molecular weights of from about 10 kDa to about 30 kDa and the PEG portion having molecular weight(s) of from about 2 kDa to about 10 kDa, with the PEG portion forming the hydrophilic shell,wherein the PLGA-PEG and PLGA-mPEG block co-polymers are present at a ratio of about 1:10 to about 2:1 by mass; wherein a portion of the PLGA-PEG polymers have a terminal attachment of a polypeptide ligand, andwherein the polypeptide ligands comprise peptide-HLA ligands and one or more of anti-CD28 and anti-4-1BB ligands.46. The aAPC of claim 45 , wherein the hydrophilic shell further comprises a mixture of PEG brushes having the same or different molecular weights.47. The aAPC of claim 45 , wherein the polymer core is based on a 20:1 to 1:20 Lactic Acid:Glycolic Acid ratio.48. The aAPC of claim 45 , wherein the polypeptide ligands are attached to PEG through primary amines on the polypeptides.49. The aAPC of claim 45 , wherein the polypeptide ligands are attached through an unpaired cysteine side chain.50. The aAPC of claim 45 , wherein the aAPC has a surface charge of about 0 to ...

Подробнее
12-11-2015 дата публикации

CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS

Номер: US20150320856A1
Принадлежит: Selecta Biosciences, Inc.

Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments. 181-. (canceled)82. A method of providing polymeric synthetic nanocarriers , comprising:(i) preparing polymeric synthetic nanocarriers that comprise an immunosuppressant coupled thereto; and(ii) administering the polymeric synthetic nanocarriers to a subject,wherein the load of the immunosuppressant on average across the first population of synthetic nanocarriers is at least 2% but no more than 25% (weight/weight), andwherein at least 80% of the polymeric synthetic nanocarriers, based on the total number of synthetic nanocarriers, have a minimum dimension or maximum dimension that falls within 20% of the average minimum dimension or the average maximum dimension, respectively, of the polymeric synthetic nanocarriers; andwherein the average minimum dimension of the polymeric synthetic nanocarriers, obtained using dynamic light scattering, is greater than 110 nm and the average maximum dimension of the polymeric synthetic nanocarriers, obtained using dynamic light scattering, is less than 500 nm.83. The method of claim 82 , wherein at least 90% of the polymeric synthetic nanocarriers have the minimum dimension or maximum dimension.84. The method of claim 83 , wherein at least 95% of the polymeric synthetic nanocarriers have the minimum dimension or maximum dimension.85. The method of claim 82 , wherein the minimum dimension or maximum dimension falls within 10%.86. The method of claim 85 , wherein the minimum dimension or maximum dimension falls within 5%.87. The method of claim 82 , wherein the average minimum dimension is equal to or greater than 120 nm.88. The method of claim 87 , wherein the average minimum dimension is equal to or greater than 130 nm.89. The method of claim 88 , wherein the average minimum dimension is equal to or greater than 150 nm. ...

Подробнее
12-11-2015 дата публикации

TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS

Номер: US20150320884A1
Принадлежит: Selecta Biosciences, Inc.

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion). 1. A method comprising:(A) administering to a subject a composition according to a protocol that was previously shown to reduce the number or activity of antigen-specific T effector cells in one or more test subjects;wherein the composition comprises:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen; or(B) reducing the number or activity of antigen-specific T effector cells in one or more test subjects by administering to the one or more test subjects a composition that comprises:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen; or(C) administering to a subject a composition that comprises:(i) a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen;wherein the composition is in an amount effective to reduce the number or activity of antigen-specific T effector cells.236-. (canceled)37. A method comprising:(i) producing a first population of synthetic nanocarriers coupled to immunosuppressants, and(ii) producing or obtaining MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen; and(iii) evaluating the effect on antigen-specific T effector cell number or activity.3846-. (canceled)47. A composition comprising:(i) a first population of synthetic nanocarriers coupled to immunosuppressants;(ii) MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen; and(iii) a pharmaceutically acceptable excipient,wherein the composition ...

Подробнее
19-11-2015 дата публикации

IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS

Номер: US20150328300A1
Принадлежит: Selecta Biosciences, Inc.

This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.

Подробнее
19-11-2015 дата публикации

DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS

Номер: US20150328309A1
Принадлежит: Selecta Biosciences, Inc.

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

Подробнее
17-10-2019 дата публикации

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT

Номер: US20190314496A1
Принадлежит: CureVac AG

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. The present invention also provides pharmaceutical compositions, particularly vaccines, comprising the inventive polymeric carrier cargo complex and the second nucleic acid molecule, as well as the use of the inventive polymeric carrier cargo complex and the second nucleic acid molecule for transfecting a cell, a tissue or an organism, as a medicament, for therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned herein. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and the second nucleic acid molecule, the inventive pharmaceutical composition and/or the inventive vaccine or any of its components in one or more parts of the kit. 1. A polymeric carrier cargo complex , comprising:a) as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components, andb) as a cargo at least one first nucleic acid molecule,for use as an immunostimulating agent or as an adjuvant,wherein the polymeric carrier cargo complex is administered in combination with at least one ...

Подробнее
23-11-2017 дата публикации

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

Номер: US20170333540A1
Принадлежит:

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases. 146.-. (canceled)47. A method of preventing or treating an autoimmune disorder , comprising administering to a subject a peptide antigen-MHC complex operatively coupled to a non-liposomal nanoparticle , wherein the nanoparticle is less than 1 μM in diameter , wherein the peptide antigen is an antigen relevant for ovarian failure , scleroderma , Sjogren's disease , lupus , vilelego , alopecia (baldness) , polyglandular failure , Grave's disease , hypothyroidism , polymyosititis , pemphigus , autoimmune hepatitis , hypopituitarism , myocardititis , Addison's disease , autoimmune skin diseases , uveititis , pernicious anemia , hypoparathyroidism , or rheumatoid arthritis , and wherein the antigen-MHC complex is administered in an amount sufficient to expand non-pathogenic autoreactive T cells.48. The method of claim 47 , wherein the antigen is derived from an autoantigen involved in the autoimmune response or a mimic thereof.49. The method of claim 47 , wherein the MHC component is a MHC class I component.50. The method of claim 49 , wherein the MHC class I component comprises all or part of a HLA-A claim 49 , HLA-B claim 49 , HLA-C claim 49 , HLA-E claim 49 , HLA-F claim 49 , HLA-G or CD-1 molecule.51. The method of claim 49 , wherein claim 49 , the MHC class I component comprises all or part of a HLA-A molecule.52. The method of claim 49 , wherein the MHC class I component comprises all or part of a HLA-A*0201 MHC class I molecule.53. ...

Подробнее
01-12-2016 дата публикации

Carbohydrate-modified particles and particulate formulations for modulating an immune response

Номер: US20160346382A1
Принадлежит: Northwestern University

Disclosed are compositions, kits, and methods for modulating an immune response. The compositions and kits include and the methods utilize carbohydrate-modified particles having an immune modulator attached at the surface of the particles. The carbohydrate-modified particles and particulate formulations comprising the carbohydrate-modified particles may be utilized for modulating an immune response in a subject.

Подробнее
22-10-2020 дата публикации

Peptide Conjugated Particles

Номер: US20200330569A1
Принадлежит:

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). 136-. (canceled)37. A composition comprising particles having a negative surface charge and comprising one or more antigen conjugated to the surface of the particles or encapsulated within the particle , wherein the particles comprise polylactide-co-glycolide (PLGA) and a polyamino acid having a carboxyl group on the side chain , wherein the particles have a negative zeta potential ranging from about −100 mV to about 0 mV.38. The composition of claim 37 , wherein the polyamino acid having a carboxyl group on the side chain is poly(aspartic acid) or poly(glutamic acid).39. The composition of claim 38 , wherein the polyamino acid having a carboxyl group on the side chain is poly(gamma-glutamic acid) claim 38 , poly(L-glutamic acid) claim 38 , poly(D-glutamic acid) claim 38 , or poly(D claim 38 ,L-glutamic acid).40. The composition of claim 37 , wherein the particles are microparticles or nanoparticles.41. The composition of claim 37 , wherein the particles have a zeta potential ranging from about −100 mV to −30 mV claim 37 , or about −75 mV to −30 mV claim 37 , or about −50 mV to −30 mV claim 37 , or about −100 mV to −50 mV claim 37 , or about −75 mV to −50 mV claim 37 , or about −50 mV to −40 mV.42. The composition of claim 37 , wherein the particles have a zeta potential of less than about −50 mV or less than about −100 mV.43. The composition of claim 37 , wherein the particles have a zeta potential ranging from about −100 mV to −30 mV44. The composition of claim 37 , wherein the PLGA has a molecular weight of 1 claim 37 ,000 Da to 100 claim 37 ,000 Da.45. The composition of claim 44 , wherein the PLGA has a molecular weight of 12 claim 44 ,000 ...

Подробнее
31-10-2019 дата публикации

MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS

Номер: US20190328871A1
Принадлежит:

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

Подробнее
17-12-2015 дата публикации

TOLEROGENIC SYNTHETIC NANOCARRIERS FOR T-CELL-MEDIATED AUTOIMMUNE DISEASE

Номер: US20150359865A1
Автор: Kishimoto Takashi Kei
Принадлежит:

Disclosed are synthetic nanocarrier compositions, and related methods, comprising autoimmune antigens and immunosuppressants to reduce immune responses to autoimmune antigens. 1. A method comprising:administering to a subject having or suspected of having a T-cell-mediated autoimmune disease or disorder a composition comprising synthetic nanocarriers coupled to an autoimmune antigen and an immunosuppressant; andadministering to the subject the composition.2. The method of claim 1 , wherein the immunosuppressant and antigen are encapsulated in the synthetic nanocarriers.3. The method of claim 1 , wherein the autoimmune antigen comprises a peptide.4. The method of claim 1 , wherein the autoimmune disease or disorder is multiple sclerosis.5. The method claim 1 , wherein the autoimmune antigen is an antigen associated with multiple sclerosis.6. The method of claim 5 , wherein the autoimmune antigen associated with multiple sclerosis comprises myelin proteolipid protein (PLP) or a peptide thereof.7. The method of claim 6 , wherein the peptide comprises PLP.8. The method of claim 1 , wherein the composition is in an amount effective to reduce or prevent an immune response to the antigen.9. The method of claim 1 , wherein the composition is in an amount effective to reduce or prevent one or more symptoms of the autoimmune disease or disorder.10. The method of claim 1 , wherein the composition is administered to the subject at least once.11. The method of claim 10 , wherein the composition is administered to the subject at least twice.12. The method of claim 1 , wherein the composition is administered to the subject at claim 1 , prior to claim 1 , or after the onset of one or more symptoms of the autoimmune disease or disorder.13. The method of claim 12 , wherein the composition is administered within two days of the onset of one or more symptoms of the autoimmune disease or disorder.14. The method of claim 1 , wherein the administering to the subject is according to a ...

Подробнее
07-11-2019 дата публикации

Bone-promoting thermoresponsive macromolecules

Номер: US20190336648A1
Принадлежит: Northwestern University

Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.

Подробнее
24-12-2015 дата публикации

Scaffolds For Cell Transplantation

Номер: US20150366956A1
Принадлежит:

A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material. 1. A cancer vaccine device comprising a scaffold composition comprising a polymer matrix and having open , interconnected macropores;a granulocyte-macrophage colony stimulating factor (GM-CSF) that recruits immune cells selected from macrophages, T-cells, B-cells, NK cells, and dendritic cells;a tumor antigen; andan immune response-promoting bioactive factor comprising an oligonucleotide, wherein the GM-CSF, the tumor antigen, or the immune response-promoting bioactive factor is incorporated into or coated onto said scaffold composition.2. The device of claim 1 , wherein said device further comprises an extracellular matrix (ECM) component.3. The device of claim 2 , wherein said ECM component comprises an arginine-glycine-aspartate (RGD) sequence.4. The device of claim 1 , wherein the GM-CSF claim 1 , tumor antigen claim 1 , or immune response-promoting bioactive factor is covalently linked to said scaffold composition.5. The device of claim 1 , wherein the tumor antigen comprises biopsy-extracted antigens.6. The device of claim 1 , wherein the tumor antigen comprises a tumor cell lysate.710-. (canceled)11. The device of claim 1 , wherein the scaffold composition degrades at a predetermined rate based on a physical parameter selected from the group consisting of temperature claim 1 , pH claim 1 , hydration status claim 1 , and porosity.12. (canceled)13. The device of claim 1 , wherein said scaffold composition comprises pores of greater than 100 μm in size.14. The device of claim 13 , wherein the scaffold composition comprises pores of 400-500 μm in size.1525-. (canceled)26. The ...

Подробнее
14-11-2019 дата публикации

CARBOHYDRATE STRUCTURES AND USES THEREOF

Номер: US20190343941A1
Принадлежит:

The present invention provides methods and compositions related to multivalent carbohydrate antigen structures comprising cancer or infection associated ganglioside carbohydrate antigens. Said carbohydrate structures may be used to induce immunity against said carbohydrate antigens. In some embodiments, carbohydrate structures may be administered to a subject thereby inducing immunity in the subject, for example, the administration of a vaccine comprising said carbohydrate structure. Also provided are methods to induce an immune response in a subject in need thereof by administering said carbohydrate structure. Further provided are methods of producing an antibody or TCR that bind said carbohydrate antigens. 3. The composition of claim 2 , wherein the substantially homogenous population is about 80% homogenous or greater.4. The composition of claim 1 , wherein the carbohydrate antigen is a tumor-associated carbohydrate antigen.5. The composition of claim 1 , wherein the tumor-associated carbohydrate antigen is a ganglioside carbohydrate antigen.6. The composition of claim 5 , wherein the ganglioside carbohydrate antigen is selected from the group consisting of GD2 claim 5 , GD3 claim 5 , GD1b claim 5 , GT1b claim 5 , fucosyl-GM1 claim 5 , GloboH claim 5 , polysialic acid (PSA) claim 5 , GM2 claim 5 , GM3 claim 5 , sialyl-LewisX claim 5 , sialyl-LewisY claim 5 , sialyl-LewisA claim 5 , sialyl-LewisB claim 5 , and LewisY.7. The composition of claim 5 , wherein the ganglioside carbohydrate antigen is GD2.8. The composition of claim 5 , wherein the ganglioside carbohydrate antigen is GD3.9. The composition of claim 1 , wherein the carbohydrate antigen is associated with an infection.10. The composition of claim 9 , wherein the infection is a bacterial infection.11. The composition of claim 9 , wherein the infection is a viral infection.12. The composition of claim 10 , wherein the viral infection is HIV claim 10 , HCV claim 10 , or Epstein-Barr virus.13. The composition ...

Подробнее
05-11-2020 дата публикации

COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

Номер: US20200345855A1
Принадлежит:

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule. 1. A pharmaceutical composition comprising:polymeric PLGA-PEG particles having a size in the range of about 100 to 200 nm, a surface charge of about 0 to -20 mV, and from about 100 to 1500 protein ligands per particle, the protein ligands optionally coupled through a sulfhydryl-maleimide chemistry;a population of anti-CD28 antibody ligands;a population of HLA ligands;one or more antigenic peptides for presentation to T cells; anda pharmaceutically acceptable carrier for intravenous, intra-arterial, subcutaneous, intradermal, intralymphatic, or intra-tumoral administration.2. (canceled)3. The pharmaceutical composition of claim 1 , wherein the PLGA is a polymer of about 50% lactic acid (LA) and 50% glycolic acid (GA).4. The pharmaceutical composition of claim 1 , wherein the PLGA polymer has a molecular weight of from about 25 kDA to about 35 kDA claim 1 , and the PEG has a molecular weight of from about 3 kDA to about 10 kDA.5. The pharmaceutical composition of claim 1 , having from 400 to 1000 ligands per particle.6. The pharmaceutical composition of claim 1 , wherein the anti-CD28 antibody ligands comprise a human IGHV4-59 germline framework optionally having from 5 to 15 murine framework residues claim 1 , and a IGKV4-01 germline framework optionally having from 3 to 15 murine framework residues.7. The pharmaceutical composition of claim 1 , wherein the anti-CD28 ligand is an antigen-binding antibody fragment.8. The pharmaceutical composition of claim 1 , wherein the anti-CD28 ligand comprises a scFv.9. The pharmaceutical composition of claim 1 , wherein the HLA ligand is ...

Подробнее
31-12-2015 дата публикации

Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors

Номер: US20150374815A1
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions and immune checkpoint inhibitor compositions and related methods for administration to a subject.

Подробнее
21-11-2019 дата публикации

NICOTINE NANOVACCINES AND USES THEREOF

Номер: US20190351037A1
Принадлежит:

Provided herein are nicotine polymer-stabilized nanoparticles, formulations thereof, and vaccines. Also provided herein are methods of treating and/or preventing nicotine addiction in a subject in need thereof. 1. (canceled)2. A nanoparticle comprising:a polymer core;a lipid shell, wherein the lipid shell encapsulates the polymer core;a first stimulating molecule, wherein the first stimulating molecule is attached to the outer surface of the lipid shell,a first nicotine-hapten antigen, wherein the first nicotine-hapten antigen is attached to the first stimulating molecule; anda second nicotine-hapten antigen, wherein the second nicotine-hapten antigen is attached to the outer surface of the lipid shell and wherein the second nicotine-hapten antigen is not attached to the first stimulating molecule.3. The nanoparticle of claim 2 , wherein the polymer core comprises poly(lactic-co-glycolic acid).4. (canceled)5. The nanoparticle of claim 2 , wherein the lipid shell comprises a lipid selected from the group consisting of: dioleoyl trimethylammonium propane (DOTAP) or a derivative thereof claim 2 , cholesterol claim 2 , DSPE (1 claim 2 ,2-Distearoylphosphatidylethanolamine)-PEG (polyethylene glycol)-maleimide claim 2 , and DSPE-PEG-amine claim 2 , a DSPE-PEG having at least one reactive terminal group claim 2 , and any combination thereof.6. The nanoparticle of claim 2 , wherein the polymer core further comprises a second stimulating molecule claim 2 , wherein the second stimulating molecule is attached to a polymer of the polymer core claim 2 , encapsulated in a polymer of the polymer core claim 2 , or both.7P. aeruginosa. The nanoparticle of claim 6 , wherein the second stimulating molecule is selected from the group consisting of: keyhole limpet hemocyanin (KLH) multimer claim 6 , KLH subunit claim 6 , tetanus toxoid (TT) claim 6 , cross-reacting material 197 (CRM197) claim 6 , bovine serum albumin (BSA) claim 6 , human papillomavirus (HPV) proteins claim 6 , ...

Подробнее
29-12-2016 дата публикации

Novel immunotherapy against several tumors including neuronal and brain tumors

Номер: US20160376314A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Подробнее
29-12-2016 дата публикации

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

Номер: US20160376315A1
Принадлежит:

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. 1. A peptide consisting of the amino acid sequence of SEQ ID NO: 21 , or a pharmaceutically acceptable salt thereof.2. A fusion protein comprising the peptide of SEQ ID NO: 21 adjoined at the N-terminus and/or the C-terminus by one or more heterologous peptides , or a pharmaceutically acceptable salt thereof.3. A kit comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) a container that contains a composition containing, in solution and/or in lyophilized. form, a peptide or salt of ;'}(b) optionally, a second container comprising a diluent and/or reconstituting solution;(c) optionally, at least one additional peptide consisting of an amino acid sequence selected from SEQ ID NOs 1-20 and 22-30, and(d) optionally, instructions for (i) use of the diluent and/or (ii) reconstitution and/or use of a lyophilized formulation.4. The kit according to claim 3 , further comprising one or more of (e) a buffer claim 3 , (f) a diluent claim 3 , (g) a filter claim 3 , (h) a needle claim 3 , and (i) a syringe.5. The fusion protein of claim 2 , wherein said one or more heterologous peptides is a carrier protein selected from keyhole limpet haemocyanin (KLH) and mannan.6. The fusion protein of claim 2 , wherein the fusion protein maintains an ability to bind to a molecule of the human major ...

Подробнее
29-12-2016 дата публикации

Novel immunotherapy against several tumors including neuronal and brain tumors

Номер: US20160376316A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Подробнее
29-12-2016 дата публикации

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

Номер: US20160376317A1
Принадлежит:

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. 1. A peptide consisting of the amino acid sequence of SEQ ID NO: 5 , or a pharmaceutically acceptable salt thereof.2. A fusion protein comprising the peptide of SEQ ID NO: 5 adjoined at the N-terminus and/or the C-terminus by one or more heterologous peptides , or a pharmaceutically acceptable salt thereof.3. A kit comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) a container that contains a composition containing, in solution and/or in lyophilized form, a peptide or salt of ;'}(b) optionally, a second container comprising a diluent and/or reconstituting solution;(c) optionally, at least one additional peptide consisting of an amino acid sequence selected from SEQ ID NOs 1-4 and 6-30, and(d) optionally, instructions for (i) use of the diluent and/or (ii) reconstitution and/or use of a lyophilized formulation.4. The kit according to claim 3 , further comprising one or more of (e) a buffer claim 3 , (f) a diluent claim 3 , (g) a filter claim 3 , (h) a needle claim 3 , and (i) a syringe.5. The fusion protein of claim 2 , wherein said one or more heterologous peptides is a carrier protein selected from keyhole limpet haemocyanin (KLH) and mannan.6. The fusion protein of claim 2 , wherein the fusion protein maintains an ability to bind to a molecule of the human major ...

Подробнее